AU2011271043A1 - Mice expressing a light chain with human lambda variable and mouse constant regions - Google Patents
Mice expressing a light chain with human lambda variable and mouse constant regions Download PDFInfo
- Publication number
- AU2011271043A1 AU2011271043A1 AU2011271043A AU2011271043A AU2011271043A1 AU 2011271043 A1 AU2011271043 A1 AU 2011271043A1 AU 2011271043 A AU2011271043 A AU 2011271043A AU 2011271043 A AU2011271043 A AU 2011271043A AU 2011271043 A1 AU2011271043 A1 AU 2011271043A1
- Authority
- AU
- Australia
- Prior art keywords
- mouse
- light chain
- human
- locus
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000699666 Mus <mouse, genus> Species 0.000 title abstract description 641
- 241000699670 Mus sp. Species 0.000 title abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 39
- 102000025171 antigen binding proteins Human genes 0.000 claims abstract description 18
- 108091000831 antigen binding proteins Proteins 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 540
- 239000012634 fragment Substances 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 72
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 59
- 108060003951 Immunoglobulin Proteins 0.000 claims description 54
- 102000018358 immunoglobulin Human genes 0.000 claims description 54
- 150000007523 nucleic acids Chemical group 0.000 claims description 50
- 239000000427 antigen Substances 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 47
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 45
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 claims description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 38
- 210000004602 germ cell Anatomy 0.000 claims description 8
- 238000000146 jump and return pulse sequence Methods 0.000 claims description 4
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 3
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 description 170
- 239000013598 vector Substances 0.000 description 97
- 101000777315 Mus musculus Choline kinase alpha Proteins 0.000 description 54
- 101000777310 Mus musculus Choline/ethanolamine kinase Proteins 0.000 description 54
- 101000974705 Mus musculus UMP-CMP kinase Proteins 0.000 description 54
- 108700028369 Alleles Proteins 0.000 description 45
- 101150076615 ck gene Proteins 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 37
- 238000003780 insertion Methods 0.000 description 32
- 230000037431 insertion Effects 0.000 description 32
- 108091029795 Intergenic region Proteins 0.000 description 31
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 29
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 29
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 28
- 238000012217 deletion Methods 0.000 description 27
- 230000037430 deletion Effects 0.000 description 27
- 229930193140 Neomycin Natural products 0.000 description 26
- 229960004927 neomycin Drugs 0.000 description 26
- 210000004988 splenocyte Anatomy 0.000 description 24
- 230000006798 recombination Effects 0.000 description 22
- 238000005215 recombination Methods 0.000 description 22
- 230000004048 modification Effects 0.000 description 21
- 238000012986 modification Methods 0.000 description 21
- 238000011144 upstream manufacturing Methods 0.000 description 20
- 210000001185 bone marrow Anatomy 0.000 description 19
- 108010091086 Recombinases Proteins 0.000 description 17
- 102000018120 Recombinases Human genes 0.000 description 17
- 238000010240 RT-PCR analysis Methods 0.000 description 16
- 239000003623 enhancer Substances 0.000 description 16
- 230000006801 homologous recombination Effects 0.000 description 15
- 238000002744 homologous recombination Methods 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 210000001161 mammalian embryo Anatomy 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 101150008942 J gene Proteins 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 108091008053 gene clusters Proteins 0.000 description 11
- 238000012239 gene modification Methods 0.000 description 11
- 230000005017 genetic modification Effects 0.000 description 11
- 235000013617 genetically modified food Nutrition 0.000 description 11
- 230000008707 rearrangement Effects 0.000 description 11
- 238000010367 cloning Methods 0.000 description 10
- 101100384399 Mus musculus C2 gene Proteins 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 101150028074 2 gene Proteins 0.000 description 7
- 101150090724 3 gene Proteins 0.000 description 7
- 101150101112 7 gene Proteins 0.000 description 7
- 101150111062 C gene Proteins 0.000 description 7
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 7
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 7
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 210000003297 immature b lymphocyte Anatomy 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 101150117115 V gene Proteins 0.000 description 6
- 230000011712 cell development Effects 0.000 description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 238000002864 sequence alignment Methods 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 101150097493 D gene Proteins 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 101150043003 Htt gene Proteins 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 101150037671 hicd gene Proteins 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 101150003288 C2 gene Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 3
- 101000777313 Homo sapiens Choline/ethanolamine kinase Proteins 0.000 description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 3
- 101001138544 Homo sapiens UMP-CMP kinase Proteins 0.000 description 3
- 102100039564 Leukosialin Human genes 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 101150003160 X gene Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 3
- 229960000268 spectinomycin Drugs 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 101150006978 J1 gene Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108091008109 Pseudogenes Proteins 0.000 description 2
- 102000057361 Pseudogenes Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 210000000472 morula Anatomy 0.000 description 2
- 108700039855 mouse a Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 101150066838 12 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150106899 28 gene Proteins 0.000 description 1
- 101150017816 40 gene Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 101100073152 Arabidopsis thaliana JAL35 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150061009 C1 gene Proteins 0.000 description 1
- OZGULPMEFXNSEB-UHFFFAOYSA-N CCC1C(CCC2)C2CC2(CCC2)C1 Chemical compound CCC1C(CCC2)C2CC2(CCC2)C1 OZGULPMEFXNSEB-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 101150042441 K gene Proteins 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 description 1
- 101100448575 Mus musculus Gli1 gene Proteins 0.000 description 1
- 101100365003 Mus musculus Scel gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101150000889 V2 gene Proteins 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 antibodies) Proteins 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Abstract
Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen- binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.
Description
WO 2011/163311 PCT/US20111/041366 MICE EXPRESSING ALIGHT CHAIN WITH HUMAN LAMBDA VARIABLE AND MOUSE CONSTANT REGIONS FIELD [0001] Genetically modified mice that comprise a mouse or human lambda variable (VX) light chain sequence operably linked with a mouse or human light chain constant region (X or kappa(x)). Genetically modified mice that express epitope-binding proteins that comprise an immunoglobulin light chain comprising a variable domain derived from a human lambda variable (hVk) gene segment, a human lambda J (hJk) gene segment, and a mouse light chain constant (CL) domain. Genetically modified mice, comprising an unrearranged immunoglobulin lambda (k) light chain variable nucleic acid sequence at an endogenous mouse light chain locus. Mice capable of rearranging and expressing a chimeric human /mouse CL light chain from an endogenous light chain locus that comprises a replacement of all endogenous mouse light chain variable region gene segments with one or more hV4 gene segments and one or more hJk gene segments. Somatically mutated antibodies comprising hVk domains and mouse CL domains. BACKGROUND [0002] Mice that express antibodies that are fully human, or partly human and partly mouse, are known in the art. For example, transgenic mice that express fully human antibodies from transgenes containing human light and heavy chain immunoglobulin variable region genes have been reported. Genetically modified mice that comprise a replacement of the endogenous mouse heavy chain variable region (HCVR) gene segments and kappa (K) light chain variable region (LCVR) gene segments with human HCVR and LCVR gene segments and that make chimeric antibodies with a chimeric human/mouse kappa chain are known as well. [0003] Antibody light chains are encoded by one of two separate loci: kappa (K) and lambda (k). Mouse antibody light chains are primarily of the K type. The ratio of K to k light chain usage in humans is about 60:40, whereas in mice it is about 95:5. Biased usage of K light chains in mice is reportedly sustained in genetically modified mice capable of expressing fully or partly human antibodies. Thus, mice that express fully or partly human antibodies appear to be constrained in lambda variable usage. [0004] There is a need in the art to generate lambda variable regions, whether mouse or human, for use in making epitope-binding proteins. There is a need in the art for mice that express fully or partly human antibodies, wherein the mice display an increased lambda variable (V) usage. 1 WO 2011/163311 PCT/US2011/041366 [0005] There is a need in the art for mice that express fully or partly human antibodies, wherein the mice display an increased X variable (V) usage. SUMMARY [0006] Genetically modified mice, embryos, cells, tissues, as well as nucleic acid constructs for modifying mice, and methods and compositions for making and using them, are provided. Mice and cells that generate lambda (k) variable regions (human or non human) in the context of a kappa (K) light chain are provided. Mice and cells that generate human k variable regions in the context of a i or a k light chain, e.g., from an endogenous mouse light chain locus, are also provided. Also provided are methods for making antibodies that comprise lambda variable regions. Methods for selecting heavy chains that express with cognate lambda variable regions are also provided. [0007] Chimeric and human antigen-binding proteins (e.g., antibodies), and nucleic acids encoding them, are provided that comprise somatically mutated variable regions, including antibodies that have light chains comprising a variable domain derived from a human VX and a human JX gene segment fused to a mouse light chain constant domain. [0008] In one aspect, a mouse is provided that expresses a human k variable region sequence on a light chain that comprises a mouse constant region. In one aspect, a mouse is provided that expresses a human k variable region sequence on a light chain that comprises a K constant region. In one aspect, a mouse is provided that expresses from an endogenous mouse light chain locus a light chain that comprises a human k variable region sequence. In one aspect, a mouse is provided that comprises a rearranged light chain gene that comprises a human k variable sequence linked to a mouse constant region sequence; in one embodiment, the mouse constant region sequence is a X constant sequence; in one embodiment, the mouse constant region sequence is a K constant sequence. [0009] In one aspect, a genetically modified mouse is provided, wherein the mouse comprises an unrearranged human k light chain variable gene segment (hV) and a human X joining gene segment (hJ). In one embodiment, the unrearranged hVk and hJX are at a mouse light chain locus. In one embodiment, the unrearranged hVk and unrearranged hJX are on a transgene and operably linked to a human or mouse constant region sequence. In one embodiment, the unrearranged hV and unrearranged hJk are on an episome. In one embodiment, the mouse is capable of making an immunoglobulin that comprises a light chain that is derived from an unrearranged hVX sequence and a hJk sequence and a mouse light chain constant region (CL) nucleic acid sequence. Methods and compositions for making and using genetically modified mice are also provided. 2 WO 2011/163311 PCT/US2011/041366 Antibodies are provided that comprise (a) a human heavy chain variable domain (hVH) fused to a mouse heavy chain constant region, and (b) a human V fused to a mouse CL domain; including wherein one or more of the variable domains are somatically mutated, e.g., during antibody or immune cell selection in a mouse of the invention. In one embodiment, the unrearranged hVk and unrearranged hJ are operably linked with a human or mouse K constant region (C). In one embodiment, the unrearranged hVk and unrearranged hJk are operably linked with a human or mouse k constant region (CX). [0010] In one aspect, a mouse is provided that comprises in its germline, at an endogenous mouse light chain locus, a human k light chain variable region sequence, wherein the human lambda variable region sequence is expressed in a light chain that comprises a mouse immunoglobulin constant region gene sequence. [0011] In one embodiment, the endogenous mouse light chain locus is a X locus. In one embodiment, the endogenous mouse light chain locus is a K locus. [0012] In one embodiment, the mouse lacks an endogenous light chain variable sequence at the endogenous mouse light chain locus. [0013] In one embodiment, all or substantially all endogenous mouse light chain variable region gene segments are replaced with one or more human k variable region gene segments. [0014] In one embodiment, the human X light chain variable region sequence comprises a human JX sequence. In one embodiment, the human JR sequence is selected from the group consisting of JR1, JX2, JR3, JR7, and a combination thereof. [0015] In one embodiment, the human X light chain variable region sequence comprises a fragment of cluster A of the human light chain locus. In a specific embodiment, the fragment of cluster A of the human X light chain locus extends from hVk3 27 through hVk3-1. [0016] In one embodiment, the human k light chain variable region sequence comprises a fragment of cluster B of the human light chain locus. In a specific embodiment, the fragment of cluster B of the human k light chain locus extends from hV5 52 through hVk1-40. [0017] In one embodiment, the human k light chain variable region sequence comprises a genomic fragment of cluster A and a genomic fragment of cluster B. In a one embodiment, the human X light chain variable region sequence comprises at least one gene segment of cluster A and at least one gene segment of cluster B. [0018] In one embodiment, more than 10% of the light chain naive repertoire of the mouse is derived from at least two hV4 gene segments selected from 2-8, 2-23, 1-40, 5-45, and 9-49. In one embodiment, more than 20% of the light chain naive repertoire of the 3 WO 2011/163311 PCT/US2011/041366 mouse is derived from at least three hVk gene segments selected from 2-8, 2-23, 1-40, 5 45, and 9-49. In one embodiment, more than 30% of the light chain naive repertoire of the mouse is derived from at least four hVk gene segments selected from 2-8, 2-23, 1-40, 5 45, and 9-49. [0019] In one aspect, a mouse is provided that expresses an immunoglobulin light chain that comprises a human X variable sequence fused with a mouse constant region, wherein the mouse exhibits a K usage to A usage ratio of about 1:1. [0020] In one embodiment, the immunoglobulin light chain is expressed from an endogenous mouse light chain locus. [0021] In one aspect, a mouse is provided that comprises a k light chain variable region sequence (VX) and at least one J sequence (J), contiguous with a mouse x light chain constant region sequence. [0022] In one embodiment, the mouse lacks a functional mouse VI and/or mouse JK gene segment. [0023] In one embodiment, the VX is a human VX (hVk), and the J is a human JR (hJk). In one embodiment, the hV and the hJR are unrearranged gene segments. [0024] In one embodiment, the mouse comprises a plurality of unrearranged hVk gene segments and at least one hJ gene segment. In a specific embodiment, the plurality of unrearranged hVk gene segments are at least 12 gene segments, at least 28 gene segments, or at least 40 gene segments. [0025] In one embodiment, the at least one hJ gene segment is selected from the group consisting of JA, Jk2, JX3, Jk7, and a combination thereof. [0026] In one embodiment, an endogenous mouse A light chain locus is deleted in whole or in part. [0027] In one embodiment, the mouse K light chain constant region sequence is at an endogenous mouse K light chain locus. [0028] In one embodiment, about 10% to about 45% of the B cells of the mouse express an antibody that comprises a light chain comprising a human k light chain variable (VX) domain and a mouse K light chain constant (CK) domain. [0029] In one embodiment, the human k variable domain is derived from a rearranged hVX/hJX sequence selected from the group consisting of 3-1/1, 3-1/7, 4-3/1, 4-3/7, 2-8/1, 3 9/1, 3-10/1, 3-10/3, 3-10/7, 2-14/1, 3-19/1, 2-23/1, 3-25/1, 1-40/1, 1-40/2, 1-40/3, 1-40/7, 7 43/1, 7-43/3, 1-44/1, 1-44/7, 5-45/1, 5-45/2, 5-45/7, 7-46/1, 7-46/2, 7-46/7, 9-49/1, 9-49/2, 9-49/7 and 1-51/1. [0030] In one embodiment, the mouse further comprises a human VK-JK intergenic region from a human K light chain locus, wherein the human VK-JK intergenic region is 4 WO 2011/163311 PCT/US2011/041366 contiguous with the VX sequence and the J sequence. In a specific embodiment, the human VK-JK intergenic region is placed between the VX sequence and the J sequence. [0031] In one aspect, a mouse is provided that comprises (a) at least 12 to at least 40 unrearranged human k light chain variable region gene segments and at least one human JR gene segment at an endogenous mouse light chain locus; (b) a human VxK-Jx intergenic sequence located between the at least 12 to at least 40 human light chain variable region gene segments and the at least one human JR sequence; wherein the mouse express an antibody that comprises a light chain comprising a human VX domain and a mouse CK domain. [0032] In one aspect, a mouse is provided that expresses an antibody comprising a light chain that comprises a k variable sequence and a x constant sequence. [0033] In one embodiment, the mouse exhibits a K usage to k usage ratio of about 1:1. [0034] In one embodiment, a population of immature B cells obtained from bone marrow of the mouse exhibits a K usage to X usage ratio of about 1:1. [0035] In one aspect, a genetically modified mouse is provided, wherein the mouse comprises an unrearranged immunoglobulin VX and a JR gene segment operably linked to a mouse light chain locus that comprises a mouse CL gene. [0036] In one embodiment, the VX and/or JR gene segments are human gene segments. In one embodiment, the VX and/or JR gene segments are mouse gene segments, and the CL is a mouse CK. [0037] In one embodiment, the endogenous mouse light chain locus is a K light chain locus. In one embodiment, the endogenous mouse light chain locus is a k light chain locus. [0038] In one embodiment, the unrearranged VX and JR gene segments are at an endogenous mouse light chain locus. [0039] In one embodiment, the unrearranged immunoglobulin VX and JR gene segments are on a transgene. [0040] In one embodiment, the mouse further comprises a replacement of one or more heavy chain V, D, and/or J gene segments with one or more human V, D, and/or J gene segments at an endogenous mouse heavy chain immunoglobulin locus. [0041] In one embodiment, the mouse comprises an unrearranged immunoglobulin VX and a JR gene segment at an endogenous mouse K light chain locus that comprises a mouse CK gene. 5 WO 2011/163311 PCT/US2011/041366 [0042] In one embodiment, the mouse comprises an unrearranged human immunoglobulin k light chain variable gene segment (V) and a k joining gene segment (JR) at an endogenous mouse k light chain locus that comprises a mouse Ck gene. [0043] In one embodiment, the light chain variable gene locus (the "VL locus") comprises at least one human Vk (hVk) gene segment. In one embodiment, the VL locus comprises at least one human JR (hJX) gene segment. In another embodiment, VL locus comprises up to four hJR gene segments. In one embodiment, the VL locus comprises a contiguous sequence comprising human k and human K genomic sequence. [0044] In one embodiment, the K light chain variable gene locus (the "K locus") comprises at least one human VX (hVX) gene segment. In one embodiment, the K locus comprises at least one human JR (hJk) gene segment. In one embodiment, the K locus comprises up to four hJR gene segments. In one embodiment, the K locus comprises at least one hVk and at least one hJR, and lacks or substantially lacks a functional VK region gene segment and lacks or substantially lacks a functional Jx region gene segment. In one embodiment, the mouse comprises no functional VK region gene segment. In one embodiment, the mouse comprises no functional JK region gene segment. [0045] In one embodiment, the k light chain variable gene locus (the "k locus") comprises at least one hVk gene segment. In one embodiment, the k locus comprises at least one human JR (hJk) gene segment. In another embodiment, the X locus comprises up to four hJR gene segments. [0046] In one embodiment, the VL locus comprises a plurality of hVs. In one embodiment, the plurality of hVAs are selected so as to result in expression of a k light chain variable region repertoire that reflects about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% or more of the Vk usage observed in a human. In one embodiment, the VL locus comprises gene segments hVk 1-40, 1-44, 2-8, 2-14, 3-21, and a combination thereof. [0047] In one embodiment, the hVks include 3-1, 4-3, 2-8, 3-9, 3-10, 2-11, and 3-12. In a specific embodiment, the VL locus comprises a contiguous sequence of the human k light chain locus that spans from VX3-12 to Vk3-1. In one embodiment, the VL locus comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hVs. In a specific embodiment, the hVks include 3-1, 4-3, 2-8, 3-9, 3-10, 2-11, and 3-12. In a specific embodiment, the VL locus comprises a contiguous sequence of the human k locus that spans from Vk3-12 to Vk3-1. In one embodiment, the VL locus is at the endogenous K locus. In a specific embodiment, the VL locus is at the endogenous K locus and the endogenous k light chain locus is deleted in part or completely. In one embodiment, the VL locus is at the 6 WO 2011/163311 PCT/US2011/041366 endogenous k locus. In a specific embodiment, the VL locus is at the endogenous k locus and the endogenous x locus is deleted in part or completely. [0048] In one embodiment, the VL locus comprises 13 to 28 or more hVAs. In a specific embodiment, the hVks include 2-14, 3-16, 2-18, 3-19, 3-21, 3-22, 2-23, 3-25, and 3-27. In a specific embodiment, the i locus comprises a contiguous sequence of the human k locus that spans from Vk3-27 to Vk3-1. In one embodiment, the VL locus is at the endogenous x locus. In a specific embodiment, the VL locus is at the endogenous K locus and the endogenous k light chain locus is deleted in part or completely. In another embodiment, the VL locus is at the endogenous k locus. In a specific embodiment, the VL locus is at the endogenous k locus and the endogenous K locus is deleted in part or completely. [0049] In one embodiment, the VL locus comprises 29 to 40 hVks. In a specific embodiment, the K locus comprises a contiguous sequence of the human k locus that spans from V3-29 to V3-1, and a contiguous sequence of the human k locus that spans from Vk5-52 to V1-40. In a specific embodiment, all or substantially all sequence between hVX1-40 and hVk3-29 in the genetically modified mouse consists essentially of a human X sequence of approximately 959 bp found in nature (e.g., in the human population) downstream of the hVk1-40 gene segment (downstream of the 3' untranslated portion), a restriction enzyme site (e.g., PI-Scel), followed by a human k sequence of approximately 3,431 bp upstream of the hVk3-29 gene segment found in nature. In one embodiment, the VL locus is at the endogenous mouse K locus. In a specific embodiment, the VL locus is at the endogenous mouse K locus and the endogenous mouse k light chain locus is deleted in part or completely. In another embodiment, the VL locus is at the endogenous mouse k locus. In a specific embodiment, the VL locus is at the endogenous mouse k locus and the endogenous mouse K locus is deleted in part or completely. [0050] In one embodiment, the VL locus comprises at least one hdk. In one embodiment, the VL locus comprises a plurality of hdks. In one embodiment, the VL locus comprises at least 2, 3, 4, 5, 6, or 7 hJX. In a specific embodiment, the VL locus comprises four hJ. In a specific embodiment, the four hJks are hJR1, hJR2, hJA3, and hJR7. In one embodiment, the VL locus is a K locus. In a specific embodiment, the VL locus is at the endogenous K locus and the endogenous k light chain locus is deleted in part or completely. In one embodiment, the VL locus comprises one hJ. In a specific embodiment, the one hJR is hJR1. In one embodiment, the VL locus is at the endogenous K locus. In a specific embodiment, the VL locus is at the endogenous K< locus and the endogenous k light chain locus is deleted in part or completely. In another embodiment, 7 WO 2011/163311 PCT/US2011/041366 the VL locus is at the endogenous k locus. In a specific embodiment, the VL locus is at the endogenous k locus and the endogenous i locus is deleted in part or completely. [0051] In one embodiment, the VL locus comprises at least one hVk, at least one hJ, and a mouse CK gene. In one embodiment, the VL locus comprises at least one hVX, at least one hJ, and a mouse Ck gene. In a specific embodiment, the mouse Ck gene is C2. In a specific embodiment, the mouse Ck gene is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, 96%, 97%, 98%, or at least 99% identical to mouse C2. [0052] In one embodiment, the mouse comprises a replacement at the endogenous mouse 1< locus of endogenous mouse Vx gene segments with one or more hV gene segments, wherein the hVX gene segments are operably linked to an endogenous mouse Cx region gene, such that the mouse rearranges the human VX gene segments and expresses a reverse chimeric immunoglobulin light chain that comprises a human VX domain and a mouse CK. In one embodiment, 90-100% of unrearranged mouse VK gene segments are replaced with at least one unrearranged hVX gene segment. In a specific embodiment, all or substantially all of the endogenous mouse VK gene segments are replaced with at least one unrearranged hVk gene segment. In one embodiment, the replacement is with at least 12, at least 28, or at least 40 unrearranged hVX gene segments. In one embodiment, the replacement is with at least 7 functional unrearranged hVX gene segments, at least 16 functional unrearranged hVX gene segments, or at least 27 functional unrearranged hVX gene segments. In one embodiment, the mouse comprises a replacement of all mouse JK gene segments with at least one unrearranged hJR gene segment. In one embodiment, the at least one unrearranged hJX gene segment is selected from JX1, JR2, JR3, JR4, JR5, JR6, JX7, and a combination thereof. In a specific embodiment, the one or more hVX gene segment is selected from a 3-1, 4-3, 2-8, 3-9, 3 10, 2-11, 3-12, 2-14, 3-16, 2-18, 3-19, 3-21, 3-22, 2-23, 3-25, 3-27, 1-40, 7-43, 1-44, 5-45, 7-46, 1-47, 5-48, 9-49, 1-50, 1-51, a 5-52 hVk gene segment, and a combination thereof. In a specific embodiment, the at least one unrearranged hJR gene segment is selected from JR1, JR2, JR3, JX7, and a combination thereof. [0053] In one embodiment, the mouse comprises a replacement of endogenous mouse VX gene segments at the endogenous mouse k locus with one or more human V) gene segments at the endogenous mouse k locus, wherein the hVX gene segments are operably linked to a mouse CX region gene, such that the mouse rearranges the hVX gene segments and expresses a reverse chimeric immunoglobulin light chain that comprises a hVX domain and a mouse Ck. In a specific embodiment, the mouse CX gene is C2. In a specific embodiment, the mouse Ck gene is at least 60%, at least 70%, at least 80%, at 8 WO 2011/163311 PCT/US2011/041366 least 90%, at least 95%, or at least 98% identical to mouse C2. In one embodiment, 90 100% of unrearranged mouse VX gene segments are replaced with at least one unrearranged hVX gene segment. In a specific embodiment, all or substantially all of the endogenous mouse VX gene segments are replaced with at least one unrearranged hVk gene segment. In one embodiment, the replacement is with at least 12, at least 28, or at least 40 unrearranged hVk gene segments. In one embodiment, the replacement is with at least 7 functional unrearranged hVk gene segments, at least 16 functional unrearranged hVk gene segments, or at least 27 functional unrearranged hVk gene segments. In one embodiment, the mouse comprises a replacement of all mouse JR gene segments with at least one unrearranged hJA gene segment. In one embodiment, the at least one unrearranged hJR gene segment is selected from JR1, Jk2, JR3, JR4, JR5, JR6, JR7, and a combination thereof. In a specific embodiment, the one or more hVk gene segment is selected from a 3-1, 4-3, 2-8, 3-9, 3-10, 2-11, 3-12, 2-14, 3-16, 2-18, 3-19, 3-21, 3-22, 2 23, 3-25, 3-27, 1-40, 7-43, 1-44, 5-45, 7-46, 1-47, 5-48, 9-49, 1-50, 1-51, a 5-52 hVk gene segment, and a combination thereof. In a specific embodiment, the at least one unrearranged hJR gene segment is selected from J1, JR2, JR3, JR7, and a combination thereof. [0054] In one aspect, a genetically modified mouse is provided that comprises a human VK-JK intergenic region sequence located at an endogenous mouse K light chain locus. [0055] In one embodiment, the human VK-JK intergenic region sequence is at an endogenous K light chain locus of a mouse that comprises a hVk and hJR gene segment, and the human VK-JK intergenic region sequence is disposed between the hVk and hJR gene segments. In a specific embodiment, the hVA and hJR gene segments are capable of recombining to form a functional human k light chain variable domain in the mouse. [0056] In one embodiment, a mouse is provided that comprises a plurality of hV's and one or more hJk's, and the human VK-JK intergenic region sequence is disposed, with respect to transcription, downstream of the proximal or 3' most hVk sequence and upstream or 5' of the first hJR sequence. [0057] In one embodiment, the human VK-JK intergenic region is a region located about 130 bp downstream or 3' of a human VK4-1 gene segment, about 130 bp downstream of the 3' untranslated region of the human VK4-1 gene segment, and spans to about 600 bp upstream or 5' of a human JK1 gene segment. In a specific embodiment, the human Vx-JK intergenic region is about 22.8 kb in size. In one embodiment, the VK-JK intergenic region is about 90% or more, 91% or more, 92% or more, 93% or more, 94% or 9 WO 2011/163311 PCT/US2011/041366 more, or about 95% or more identical with a human VK-JK intergenic region extending from the end of the 3' untranslated region of a human VK4-1 gene segment to about 600 bp upstream of a human JK1 gene segment. In one embodiment, the VK-JK intergenic region comprises SEQ ID NO:100. In a specific embodiment, the VK-JK intergenic region comprises a functional fragment of SEQ ID NO:100. In a specific embodiment, the VK-JK intergenic region is SEQ ID NO:100. [0058] In one aspect, a mouse, a mouse cell (e.g., a mouse embryonic stem cell), a mouse embryo, and a mouse tissue are provided that comprise the recited human VK-JK intergenic region sequence, wherein the intergenic region sequence is ectopic. In a specific embodiment, the ectopic sequence is placed at a humanized endogenous mouse immunoglobulin locus. [0059] In one aspect, an isolated nucleic acid construct is provided that comprises the recited human VK-JK intergenic region sequence. In one embodiment, the nucleic acid construct comprises targeting arms to target the human VK-JK intergenic region sequence to a mouse light chain locus. In a specific embodiment, the mouse light chain locus is a x locus. In a specific embodiment, the targeting arms target the human VK-JK intergenic region to a modified endogenous mouse K locus, wherein the targeting is to a position between a hVk sequence and a hJk sequence. [0060] In one aspect, a genetically modified mouse is provided, wherein the mouse comprises no more than two light chain alleles, wherein the light chain alleles comprise (a) an unrearranged immunoglobulin human VX and a JX gene segment at an endogenous mouse light chain locus that comprises a mouse CL gene; and, (b) an unrearranged immunoglobulin VL and a JL gene segment at an endogenous mouse light chain locus that comprises a mouse CL gene. [0061] In one embodiment, the endogenous mouse light chain locus is a K locus. In another embodiment, the endogenous mouse light chain locus is a k locus. [0062] In one embodiment, the no more than two light chain alleles are selected from a K allele and a k allele, two K alleles, and two k alleles. In a specific embodiment, one of the two light chain alleles is a k allele that comprises a C2 gene. [0063] In one embodiment, the mouse comprises one functional immunoglobulin light chain locus and one nonfunctional light chain locus, wherein the functional light chain locus comprises an unrearranged immunoglobulin human VX and a JR gene segment at an endogenous mouse K light chain locus that comprises a mouse CK gene. [0064] In one embodiment, the mouse comprises one functional immunoglobulin light chain locus and one nonfunctional light chain locus, wherein the functional light chain locus comprises an unrearranged immunoglobulin human VX and a JR gene segment at an 10 WO 2011/163311 PCT/US2011/041366 endogenous mouse X light chain locus that comprises a mouse Ck gene. In one embodiment, the Ck gene is C2. In a specific embodiment, the mouse Ck gene is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse C2. [0065] In one embodiment, the mouse further comprises at least one immunoglobulin heavy chain allele. In one embodiment, the at least one immunoglobulin heavy chain allele comprises a human VH gene segment, a human DH gene segment, and a human JH gene segment at an endogenous mouse heavy chain locus that comprises a human heavy chain gene that expresses a human/mouse heavy chain. In a specific embodiment, the mouse comprises two immunoglobulin heavy chain alleles, and the mouse expresses a human/mouse heavy chain. [0066] In one embodiment, the mouse comprises a first light chain allele that comprises an unrearranged hVK and an unrearranged hJK, at an endogenous mouse K locus that comprises an endogenous CK gene; and a second light chain allele that comprises an unrearranged hVk and an unrearranged hJ, at an endogenous mouse K locus that comprises an endogenous CK gene. In a specific embodiment, the first and the second light chain alleles are the only functional light chain alleles of the genetically modified mouse. In a specific embodiment, the mouse comprises a nonfunctional k locus. In one embodiment, the genetically modified mouse does not express a light chain that comprises a k constant region. [0067] In one embodiment, the mouse comprises a first light chain allele that comprises an unrearranged hVK and an unrearranged hJK, at an endogenous mouse K locus that comprises an endogenous Cx gene; and a second light chain allele that comprises an unrearranged hVk and an unrearranged hJ, at an endogenous mouse k locus that comprises an endogenous Ck gene. In a specific embodiment, the first and the second light chain alleles are the only functional light chain alleles of the genetically modified mouse. In one embodiment, the endogenous Ck gene is C2. In a specific embodiment, the mouse CX gene is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse C2. [0068] In one embodiment, the mouse comprises six immunoglobulin alleles, wherein the first allele comprises an unrearranged immunoglobulin VX and JX gene segment at an endogenous mouse K light chain locus that comprises a mouse CK gene, the second comprises an unrearranged immunoglobulin VK and JK gene segment at an endogenous mouse K light chain locus that comprises a mouse CK gene, the third comprises an unrearranged immunoglobulin VX and JX gene segment at an endogenous mouse X light 11 WO 2011/163311 PCT/US2011/041366 chain locus that comprises a mouse Ck gene, the fourth and fifth each independently comprise an unrearranged VH and DH and JH gene segment at an endogenous mouse heavy chain locus that comprises a mouse heavy chain gene, and the sixth comprises either (a) an unrearranged immunoglobulin Vk and Jk gene segment at an endogenous mouse K light chain locus that comprises a mouse Ck gene, (b) a k locus that is nonfunctional, or (c) a deletion in whole or in part of the X locus. [0069] In one embodiment, the first allele comprises an unrearranged hVk and hJ. In one embodiment, the second allele comprises an unrearranged hVK and hJK. In one embodiment, the third allele comprises an unrearranged hVk and hJ. In one embodiment, the fourth and fifth each independently comprise an unrearranged hVH and hDH and hJH. In one embodiment, the sixth allele comprises an endogenous mouse k locus that is deleted in whole or in part. [0070] In one embodiment, the mouse comprises six immunoglobulin alleles, wherein the first allele comprises an unrearranged immunoglobulin VX and JA gene segment at an endogenous mouse k light chain locus that comprises a mouse Ck gene, the second comprises an unrearranged immumoglobulin VX and JA gene segment at an endogenous mouse k light chain locus that comprises a mouse Ck gene, the third comprises an unrearranged immunoglobulin Vi and JK gene segment at an endogenous mouse K light chain locus that comprises a mouse CK gene, the fourth and fifth each independently comprise an unrearranged VH and DH and JH gene segment at an endogenous mouse heavy chain locus that comprises a mouse heavy chain gene, and the sixth comprises either (a) an unrearranged immunoglobulin Vx and JK gene segment at an endogenous mouse K light chain locus that comprises a mouse C gene, (b) a K locus that is nonfunctional, or (c) a deletion of one or more elements of the K locus. [0071] In one embodiment, the first allele comprises an unrearranged hVX and hJX gene segment. In one embodiment, the second allele comprises an unrearranged hVX and hJA gene segment. In one embodiment, the third allele comprises an unrearranged hVK and hJK gene segment. In one embodiment, the fourth and fifth each independently comprise an unrearranged hVH and hDH and hJH gene segment. In one embodiment, the sixth allele comprises an endogenous mouse K locus that is functionally silenced. [0072] In one embodiment, the genetically modified mouse comprises a B cell that comprises a rearranged antibody gene comprising a rearranged hVX domain operably linked to a mouse CL domain. In one embodiment, the mouse CL domain is selected from a mouse CK and a mouse CX domain. In a specific embodiment, the mouse Ck domain is derived from a C2 gene. In a specific embodiment, the mouse Ck domain is derived from 12 WO 2011/163311 PCT/US2011/041366 a Ck domain that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse CA2. [0073] In one aspect, a genetically modified mouse is provided that expresses a Vk region on a CL that is a CK. In one aspect, a genetically modified mouse is provided that expresses a hVX region on a CL selected from a human CK, a human Ck, or a mouse CK. In one aspect, a genetically modified mouse is provided that expresses a hVk region on a mouse CK. [0074] In one embodiment, about 10-50% of the splenocytes of the mouse are B cells (i.e., CD1 9-positive), or which about 9-28% express an immunoglobulin light chain comprising a hVk domain fused to a mouse CK domain. [0075] In a specific embodiment, about 23-34% of the splenocytes of the mouse are B cells (i.e., CD19-positive), or which about 9-11% express an immunoglobulin light chain comprising a hVk domain fused to a mouse CK domain. [0076] In a specific embodiment, about 19-31% of the splenocytes of the mouse are B cells (i.e., CD1 9-positive), or which about 9-17% express an immunoglobulin light chain comprising a hVk domain fused to a mouse CK domain. [0077] In a specific embodiment, about 21-38% of the splenocytes of the mouse are B cells (i.e., CD1 9-positive), or which about 24-27% express an immunoglobulin light chain comprising a hVk domain fused to a mouse CK domain. [0078] In a specific embodiment, about 10-14% of the splenocytes of the mouse are B cells (i.e., CD19-positive), or which about 9-13% express an immunoglobulin light chain comprising a hV domain fused to a mouse CK domain. [0079] In a specific embodiment, about 31-48% of the splenocytes of the mouse are B cells (i.e., CD1 9-positive), or which about 15-21% express an immunoglobulin light chain comprising a hVk domain fused to a mouse Cx domain. In a specific embodiment, about 30-38% of the splenocytes of the mouse are B cells (i.e., CD19-positive), of which about 33-48% express an immunoglobulin light chain comprising a hVk domain fused to a mouse C domain. [0080] In one embodiment, about 52-70% of the bone marrow of the mouse are B cells (i.e., CD19-positive), or which about 31-47% of the immature B cells (i.e., CD19 positive/B220-intermediate positive/IgM-positive) express an immunoglobulin light chain comprising a hVX domain fused to a mouse Cx domain. [0081] In one embodiment, about 60% of the bone marrow of the mouse are B cells (i.e., CD1 9-positive), or which about 38.3% of the immature B cells (i.e., CD19 positive/B220-intermediate positive/IgM-positive) express an immunoglobulin light chain comprising a hVk domain fused to a mouse CK domain. 13 WO 2011/163311 PCT/US2011/041366 [0082] In one embodiment, the mouse expresses an antibody comprising a light chain that comprises a variable domain derived from a human V and a human J gene segment, and a constant domain derived from a mouse constant region gene. In one embodiment, the mouse constant region gene is a CK gene. In another embodiment, the mouse constant region gene is a Ck gene. In a specific embodiment, the Ck region is CU2. In a specific embodiment, the mouse Ck gene is derived from a CX gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse CX2. In a specific embodiment, the antibody further comprises a heavy chain comprising a variable domain derived from a human V, a human D and a human J gene segment, and a heavy chain constant domain derived from a mouse heavy chain constant region gene. In one embodiment, the mouse heavy chain constant region gene comprises a hinge-CH 2 CH 3 sequence of a heavy chain constant domain. In another embodiment, the mouse heavy chain constant region gene comprises a CH-hinge-CH 2
-CH
3 sequence of a heavy chain constant domain. In another embodiment, the mouse heavy chain constant region gene comprises a CH-CH 2
-CH
3
-CH
4 sequence of a heavy chain constant domain. In another embodiment, the mouse heavy chain constant region gene comprises a CH 2
-CH
3 CH 4 sequence of a heavy chain constant domain. [0083] In one embodiment, the mouse expresses an antibody comprising a light chain that comprises a rearranged human VX-JX sequence and a mouse CK sequence. In one embodiment, the rearranged human VX-Jk sequence is derived from a rearrangement of hVk gene segments selected from a 3-1, 4-3, 2-8, 3-9, 3-10, 2-14, 3-19, 2-23, 3-25, 1-40, 7-43, 1-44, 5-45, 7-46, 1-47, 9-49, and a 1-51 gene segment. In one embodiment, the rearranged human VX-JX sequence is derived from a rearrangement of hJX gene segments selected from JR1, JR2, JR3, and a JX7 gene segment. [0084] In one embodiment, the mouse expresses an antibody comprising a light chain that comprises a rearranged immunoglobulin k light chain variable region comprising a human Vk/JX sequence selected from 3-1/1, 3-1/7, 4-3/1, 4-3/7, 2-8/1, 3-9/1, 3-10/1, 3 10/3, 3-10/7, 2-14/1, 3-19/1, 2-23/1, 3-25/1, 1-40/1, 1-40/2, 1-40/3, 1-40/7, 7-43/1, 7-43/3, 1-44/1, 1-44/7, 5-45/1, 5-45/2, 5-45/7, 7-46/1, 7-46/2, 7-46/7, 9-49/1, 9-49/2, 9-49/7 and 1 51/1. In a specific embodiment, the B cell expresses an antibody comprising a human immunoglobulin heavy chain variable domain fused with a mouse heavy chain constant domain, and a human immunoglobulin k light chain variable domain fused with a mouse K light chain constant domain. [0085] In one aspect, a mouse is provided that expresses an antibody comprising (a) a heavy chain comprising a heavy chain variable domain derived from an unrearranged human heavy chain variable region gene segment, wherein the heavy chain variable 14 WO 2011/163311 PCT/US2011/041366 domain is fused to a mouse heavy chain constant (CH) region; and, (b) a light chain comprising a light chain variable domain derived from an unrearranged hVk and a hJ, wherein the light chain variable domain is fused to a mouse CL region. [0086] In one embodiment, the mouse comprises (i) a heavy chain locus that comprises a replacement of all or substantially all functional endogenous mouse V, D and J gene segments with all or substantially all functional human V, D, and J gene segments, a mouse CH gene, (ii) a first K light chain locus comprising a replacement of all or substantially all functional endogenous mouse Vi and JK gene segments with all, substantially all, or a plurality of, functional hVk and hJR gene segments, and a mouse CK gene, (iii) a second K light chain locus comprising a replacement of all or substantially all functional endogenous mouse VK and JK gene segments with all, substantially all, or a plurality of, functional hVK and hJK gene segments, and a mouse CK gene. In one embodiment, the mouse does not express an antibody that comprises a C region. In one embodiment, the mouse comprises a deletion of a C gene and/or a Vk and/or a JR gene segment. In one embodiment, the mouse comprises a nonfunctional k light chain locus. In a specific embodiment, the k light chain locus is deleted in whole or in part. [0087] In one embodiment, the mouse comprises (i) a heavy chain locus that comprises a replacement of all or substantially all functional endogenous mouse V, D and J gene segments with all or substantially all functional human V, D, and J gene segments, a mouse CH gene, (ii) a first k light chain locus comprising a replacement of all or substantially all functional endogenous mouse Vk and JR gene segments with all, substantially all, or a plurality of, functional hVX and hJR gene segments, and a mouse C gene, (iii) a second k light chain locus comprising a replacement of all or substantially all functional endogenous mouse VX and JR gene segments with all, substantially all, or a plurality of, functional hV and hJR gene segments, and a mouse CX gene. In a specific embodiment, the mouse C gene is CU2. In a specific embodiment, the mouse CX gene is derived from a C gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse CU2. [0088] In one embodiment, the mouse comprises a deletion of a Cx gene and/or a VK and/or a JK gene segment. In one embodiment, the mouse comprises a nonfunctional x light chain locus. [0089] In one aspect, a genetically modified mouse that expresses an antibody is provided, wherein greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 60%, greater than 70%, greater than 80%, or greater than 90% of total IgG antibody produced by the 15 WO 2011/163311 PCT/US2011/041366 mouse comprises a k-derived variable domain, and wherein the mouse expresses antibodies comprising a K-derived variable domain fused with a mouse CK region. In specific embodiments, about 15-40%, 20-40%, 25-40%, 30-40%, or 35-40% of total antibody produced by the mouse comprises a K-derived variable domain. [0090] In one embodiment, the K-derived variable domain is derived from a hVk and a hJk. In one embodiment, the k-derived variable domain is in a light chain that comprises a mouse CK region. In a specific embodiment, the k-derived variable region is in a light chain that comprises a mouse Ck region. In another specific embodiment, the Ck region is a C2 region. In one embodiment, the K-derived variable domain is derived from a hVK and a hJK, and in a specific embodiment is in a light chain that comprises a mouse CK region. [0091] In one aspect, an isolated DNA construct is provided that comprises an upstream homology arm and a downstream homology arm, wherein the upstream and the downstream homology arms target the construct to a mouse K locus, and the construct comprises a functional unrearranged hVK segment and a functional unrearranged hJK segment, and a selection or marker sequence. [0092] In one aspect, an isolated DNA construct is provided, comprising, from 5' to 3' with respect to the direction of transcription, a targeting arm for targeting a mouse k sequence upstream of mouse VK2, a selection cassette flanked 5' and 3' with recombinase recognition sites, and a targeting arm for targeting a mouse k sequence 3' of mouse JK2. In one embodiment, the selection cassette is a Frt'ed Hyg-TK cassette. In one embodiment, the 3' targeting arm comprises mouse CK2, JK4, CK4, and mouse enhancer 2.4. [0093] In one aspect, an isolated DNA construct is provided, comprising, from 5' to 3' with respect to the direction of transcription, a targeting arm for targeting the mouse k locus 5' with respect to VK1, a selection cassette flanked 5' and 3' with recombinase recognition sites, and a 3' targeting arm for targeting a mouse k sequence 3' with respect to mouse C1. In one embodiment, the selection cassette is a loxed neomycin cassette. In one embodiment, the 3' targeting arm comprises the mouse k 3' enhancer and mouse k 3' enhancer 3.1. [0094] In one aspect, an isolated DNA construct is provided, comprising from 5' to 3' with respect to the direction of transcription, a targeting arm for targeting the mouse k locus 5' with respect to VK2, a selection cassette flanked 5' and 3' with recombinase recognition sites, and a 3' targeting arm for targeting a mouse k sequence 3' with respect to mouse JK2 and 5' with respect to mouse CK2. In one embodiment, the selection cassette is a 16 WO 2011/163311 PCT/US2011/041366 Frt'ed hygromycin-TK cassette. In one embodiment, the 3' targeting arm comprises the mouse C2-Jk4-C4 gene segments and mouse k enhancer 2.4. [0095] In one aspect, an isolated DNA construct is provided, comprising, from 5' to 3' with respect to the direction of transcription, a targeting arm for targeting the mouse k locus 5' with respect to V2, a selection cassette flanked 5' and 3' with recombinase recognition sites, a human genomic fragment comprising a contiguous region of the human k light chain locus from hVk3-12 downstream to the end of hJk1, and a 3' targeting arm for targeting a mouse k sequence 3' with respect to mouse JR2. In one embodiment, the selection cassette is a Frt'ed neomycin cassette. In one embodiment, the 3' targeting arm comprises the mouse C2-J4-C4 gene segments and mouse k enhancer 2.4. [0096] In one aspect, an isolated DNA construct is provided, comprising a contiguous region of the human k light chain locus from hVk3-12 downstream to the end of hJ1. [0097] In one aspect, an isolated DNA construct is provided, comprising, from 5' to 3' with respect to the direction of transcription, a targeting arm for targeting the mouse X locus 5' with respect to V2, a selection cassette flanked 5' and 3' with recombinase recognition sites and a human genomic fragment comprising a contiguous region of the human k light chain locus from hVk3-27 downstream to the end of hVk2-8. In one embodiment, the selection cassette is a Frt'ed hygromycin cassette. In one embodiment, the human genomic fragment comprises a 3' targeting arm. In a specific embodiment, the 3' targeting arm comprises about 53 kb of the human k light chain locus from hVk3-12 downstream to the end of hVk2-8. [0098] In one aspect, an isolated DNA construct is provided, comprising a contiguous region of the human k light chain locus from hV3-27 downstream to the end of hVX3-12. [0099] In one aspect, an isolated DNA construct is provided, comprising, from 5' to 3' with respect to the direction of transcription, a targeting arm for targeting the mouse k locus 5' with respect to V2, a selection cassette flanked 5' and 3' with recombinase recognition sites, a first human genomic fragment comprising a contiguous region of the human k light chain locus from hV5-52 downstream to the end of hVX1-40, a restriction enzyme site, and a second human genomic fragment comprising a contiguous region of the human ? light chain locus from hV3-29 downstream to the end of hVk82K. In one embodiment, the selection cassette is a Frt'ed neomycin cassette. In one embodiment, the restriction enzyme site is a site for a homing endonuclease. In a specific embodiment, the homing endonuclease is PI-Scel. In on embodiment, the second human genomic fragment is a 3' targeting arm. In a specific embodiment, the 3' targeting arm comprises about 27 kb of the human k light chain locus from hVk3-29 downstream to the end of hVk82K. 17 WO 2011/163311 PCT/US2011/041366 [00100] In one aspect, an isolated DNA construct is provided, comprising a contiguous region of the human X light chain locus from hVk5-52 downstream to the end of hVX1 -40. [00101] In one aspect, an isolated DNA construct is provided, comprising, from 5' to 3' with respect to the direction of transcription, a targeting arm for targeting the mouse K locus 5' with respect to the endogenous VK gene segments, two juxtaposed recombinase recognition sites, a selection cassette 3' to the juxtaposed recombinase recognition sites, and a 3' targeting arm for targeting a mouse K sequence 5' with respect to the K light chain variable gene segments. In one embodiment, the juxtaposed recombinase recognition sites are in opposite orientation with respect to one another. In a specific embodiment, the recombinase recognition sites are different. In another specific embodiment, the recombinase recognition sites are a loxP site and a lox511 site. In one embodiment, the selection cassette is a neomycin cassette. [00102] In one aspect, an isolated DNA construct is provided, comprising, from 5' to 3' with respect to the direction of transcription, a targeting arm for targeting the mouse K locus 5' with respect to the mouse JK gene segments, a selection cassette, a recombinase recognition site 3' to the selection cassette, and a 3' targeting arm for targeting a mouse K sequence 3' with respect to the mouse JK gene segments and 5' to the mouse K intronic enhancer. In one embodiment, the selection cassette is a hygromycin-TK cassette. In one embodiment, the recombinase recognition site is in the same direction with respect to transcription as the selection cassette. In a specific embodiment, the recombinase recognition site is a loxP site. [00103] In one aspect, an isolated DNA construct is provided, comprising, from 5' to 3' with respect to the direction of transcription, a first mouse genomic fragment comprising sequence 5' of the endogenous mouse VK gene segments, a first recombinase recognition site, a second recombinase recognition site, and a second mouse genomic fragment comprising sequence 3' of the endogenous mouse JK gene segments and 5' of the mouse K intronic enhancer. [00104] In one aspect, a genetically modified mouse is provided, wherein the genetic modification comprises a modification with one or more of the DNA constructs described above or herein. [00105] In one aspect, use of an isolated DNA construct to make a mouse as described herein is provided. In one aspect, use of an isolated DNA construct as described herein in a method for making an antigen-binding protein is provided. [00106] In one aspect, a non-human stem cell is provided that comprises a targeting vector that comprises a DNA construct as described above and herein. In one aspect, a 18 WO 2011/163311 PCT/US2011/041366 non-human stem cell is provided, wherein the non-human stem cell is derived from a mouse described herein. [00107] In one embodiment, the non-human stem cell is an embryonic stem (ES) cell. In a specific embodiment, the ES cell is a mouse ES cell. [00108] In one aspect, use of a non-human stem cell as described herein to make a mouse as described herein is provided. In one aspect, use of a non-human stem cell as described herein to make an antigen-binding protein is provided. [00109] In one aspect, a mouse embryo is provided, wherein the mouse embryo comprises a genetic modification as provided herein. In one embodiment, a host mouse embryo that comprises a donor ES cell is provided, wherein the donor ES cell comprises a genetic modification as described herein. In one embodiment, the mouse embryo is a pre morula stage embryo. In a specific embodiment, the pre-morula stage embryo is a 4-cell stage embryo or an 8-cell stage embryo. In another specific embodiment, the mouse embryo is a blastocyst. [00110] In one aspect, use of a mouse embryo as described herein to make a mouse as described herein is provided. In one aspect, use of a mouse embryo as described herein to make an antigen-binding protein is provided. [00111] In one aspect, a non-human cell is provided, wherein the non-human cell comprises a rearranged immunoglobulin light chain gene sequence derived from a genetically modified mouse as described herein. In one embodiment, the cell is a B cell. In one embodiment, the cell is a hybridoma. In one embodiment, the cell encodes an immunoglobulin light chain variable domain and/or an immunoglobulin heavy chain variable domain that is somatically mutated. [00112] In one aspect, a non-human cell is provided, wherein the non-human cell comprises a rearranged immunoglobulin light chain gene sequence derived from a genetically modified mouse as described herein. In one embodiment, the cell is a B cell. In one embodiment, the cell is a hybridoma. In one embodiment, the cell encodes an immunoglobulin light chain variable domain and/or an immunoglobulin heavy chain variable domain that is somatically mutated. [00113] In one aspect, use of a non-human cell as described herein to make a mouse as described herein is provided. In one aspect, use of a non-human cell as described herein to make an antigen-binding protein is provided. [00114] In one aspect, a mouse B cell is provided that expresses an immunoglobulin light chain that comprises (a) a variable region derived from a hVk gene segment and a hJA gene segment; and, (b) a mouse CL gene. In one embodiment, the mouse CL gene is selected from a CK and a Ck gene. In a specific embodiment, the Ck gene is C2. In a 19 WO 2011/163311 PCT/US2011/041366 specific embodiment, the mouse CX gene is derived from a Ck gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse C2. In one embodiment, the mouse B cell further expresses a cognate heavy chain that comprises (c) a variable region derived from a hVH, a hDH, and (d) a hJH segment. In one embodiment, the B cell does not comprise a rearranged k gene. In another embodiment, the B cell does not comprise a rearranged K gene. [00115] In one aspect, a method for making an antibody in a genetically modified mouse is provided, comprising: (a) exposing a genetically modified mouse to an antigen, wherein the mouse has a genome comprising at least one hVk and at least one hJA at an endogenous light chain locus, wherein the endogenous light chain locus comprises a mouse CL gene; (b) allowing the genetically modified mouse to develop an immune response to the antigen; and, (c) isolating from the mouse of (b) an antibody that specifically recognizes the antigen, or isolating from the mouse of (b) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, wherein the antibody comprises a light chain derived from a hVk, a hJk and a mouse CL gene. In a specific embodiment, the mouse CL gene is a mouse CK gene. [00116] In one embodiment, a method for making an antibody in a genetically modified mouse is provided, comprising: (a) exposing a genetically modified mouse to an antigen, wherein the mouse has a genome comprising at least one hV at an endogenous K locus and at least one hJ at the K locus, wherein the K locus comprises a mouse Ci gene; (b) allowing the genetically modified mouse to develop an immune response to the antigen; and, (c) isolating from the mouse of (b) an antibody that specifically recognizes the antigen, or isolating from the mouse of (b) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, wherein the antibody comprises a light chain derived from a hVX, a hJ and a mouse CK gene. [00117] In one embodiment, the K light chain constant gene is selected from a human CK gene and a mouse CK gene. [00118] In one embodiment, a method for making an antibody in a genetically modified mouse is provided, comprising: (a) exposing a genetically modified mouse to an antigen, wherein the mouse has a genome comprising at least one hVk at a k light chain locus and at least one JR at the X light chain locus, wherein the k light chain locus comprises a mouse CA gene; (b) allowing the genetically modified mouse to develop an immune response to the antigen; and, (c) isolating from the mouse of (b) an antibody that specifically recognizes the antigen, or isolating from the mouse of (b) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, or identifying in the mouse of B a nucleic acid sequence encoding a heavy and/or light chain variable domain that 20 WO 2011/163311 PCT/US2011/041366 binds the antigen, wherein the antibody comprises a light chain derived from a hVX, a hJR and a mouse Ck gene. [00119] In one embodiment, the k light chain constant gene is selected from a human Ck gene and a mouse CX gene. In one embodiment, the k light chain constant gene is a human Ck gene. In a specific embodiment, the human Ck gene is selected from C1, C2, CX3 and C7. In one embodiment, the k light chain constant gene is a mouse CX gene. In a specific embodiment, the mouse CX gene is selected from CU1, CX2 and C3. In a more specific embodiment, the mouse CX gene is CM2. In another specific embodiment, the mouse CX gene is derived from a CX gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse CX2. [00120] In one aspect, a method for making a rearranged antibody gene in a genetically modified mouse is provided, comprising: (a) exposing a genetically modified mouse to an antigen, wherein the genetic modification comprises a hVX and a hJX at an endogenous light chain locus, wherein the endogenous light chain locus comprises a mouse CL gene or functional fragment thereof; and, (b) identifying a rearranged immunoglobulin gene in said mouse, wherein the rearranged immunoglobulin gene comprises a k light chain variable region gene segment and a CL gene or functional fragment thereof. [00121] In one embodiment, the method further comprises cloning a nucleic acid sequence encoding a heavy and/or light chain variable region from the mouse, wherein the heavy and/or light chain variable region is from an antibody that comprises a human VX and a mouse CL. [00122] In one embodiment, the mouse CL gene or functional fragment thereof is selected from a human CL gene and a mouse CL gene, or functional fragment thereof. [00123] In one embodiment, a method for making a rearranged antibody gene in a genetically modified mouse is provided, comprising: (a) exposing a genetically modified mouse to an antigen, wherein the genetic modification comprises a hVX and a hJX at a K light chain locus, wherein the K light chain locus comprises a mouse CK gene or functional fragment thereof; and, (b) identifying a rearranged immunoglobulin gene in said mouse, wherein the rearranged immunoglobulin gene comprises a k light chain variable region gene segment and a CK gene or functional fragment thereof. [00124] In one embodiment, the K light chain constant gene or functional fragment thereof is selected from a human CK gene and a mouse Cx gene, or a functional fragment thereof. [00125] In one embodiment, the method further comprises cloning a nucleic acid sequence encoding a heavy and/or light chain variable region from the mouse, wherein the 21 WO 2011/163311 PCT/US2011/041366 heavy and/or light chain variable region is from an antibody that comprises a human Vk and a mouse Cx. [00126] In one embodiment, a method for making a rearranged antibody gene in a genetically modified mouse is provided, comprising: (a) exposing a genetically modified mouse to an antigen, wherein the genetic modification comprises a hVX and a hJX at a mouse k light chain locus, wherein the k light chain locus comprises a mouse Ck gene or functional fragment thereof; and, (b) identifying a rearranged immunoglobulin gene in said mouse, wherein the rearranged immunoglobulin gene comprises a K light chain variable region gene segment and a CX gene or functional fragment thereof. [00127] In one embodiment, the k light chain constant gene or functional fragment thereof is selected from a human Ck gene and a mouse Ck gene, or a functional fragment thereof. In a specific embodiment, the k light chain constant gene is a mouse Ck gene, or a functional fragment thereof. [00128] In one embodiment, the method further comprises cloning a nucleic acid sequence encoding a heavy and/or light chain variable region from the mouse, wherein the heavy and/or light chain variable region is from an antibody that comprises a human Vk and a mouse Ck. [00129] In one aspect, a method for making an antibody is provided, comprising exposing a mouse as described herein to an antigen, allowing the mouse to mount an immune response that comprises making an antibody that specifically binds the antigen, identifying a rearranged nucleic acid sequence in the mouse that encodes heavy chain and a rearranged nucleic acid sequence in the mouse that encodes a cognate light chain variable domain sequence of an antibody, wherein the antibody specifically binds the antigen, and employing the nucleic acid sequences of the heavy and light chain variable domains fused to human constant domains to make a desired antibody, wherein the desired antibody comprises a light chain that comprises a VX domain fused to a CL domain. In one embodiment, the Vk domain is human and the CL domain is a human or mouse CX domain. In one embodiment, the VX domain is mouse and the CL domain is a human or mouse CK domain. [00130] In one embodiment, a method for making an antibody is provided, comprising exposing a mouse as described herein to an antigen, allowing the mouse to mount an immune response that comprises making an antibody that specifically binds the antigen, identifying a rearranged nucleic acid sequence in the mouse that encodes a heavy chain and a rearranged nucleic acid sequence in the mouse that encodes a cognate light chain variable domain sequence of an antibody, wherein the antibody specifically binds the antigen, and employing the nucleic acid sequences of the heavy and light chain variable 22 WO 2011/163311 PCT/US2011/041366 domains fused to nucleic acid sequences of human constant domains to make a desired antibody, wherein the desired antibody comprises a light chain that comprises a V domain fused to a Cx domain. [00131] In one embodiment, a method for making an antibody is provided, comprising exposing a mouse as described herein to an antigen, allowing the mouse to mount an immune response that comprises making an antibody that specifically binds the antigen, identifying a rearranged nucleic acid sequence in the mouse that encodes a heavy chain variable domain and a rearranged nucleic acid sequence that encodes a cognate light chain variable domain sequence of an antibody, wherein the antibody specifically binds the antigen, and employing the nucleic acid sequences fused to nucleic acid sequences that encode a human heavy chain constant domain and a human light chain constant domain to make an antibody derived from human sequences, wherein the antibody that specifically binds the antigen comprises a light chain that comprises a human Vk domain fused to a mouse Ck region. [00132] In one embodiment, the mouse Ck region is selected from C1, C2 and C3. In a specific embodiment, the mouse Ck region is C2. [00133] In one aspect, a method for making a rearranged antibody light chain variable region gene sequence is provided, comprising (a) exposing a mouse as described herein to an antigen; (b) allowing the mouse to mount an immune response; (c) identifying a cell in the mouse that comprises a nucleic acid sequence that encodes a rearranged human VA domain sequence fused with a mouse CL domain, wherein the cell also encodes a cognate heavy chain comprising a human VH domain and a mouse CH domain, and wherein the cell expresses an antibody that binds the antigen; (d) cloning from the cell a nucleic acid sequence encoding the human VA domain and a nucleic acid sequence encoding the cognate human VH domain; and, (e) using the cloned nucleic acid sequence encoding the human V? domain and the cloned nucleic acid sequence encoding the cognate human VH domain to make a fully human antibody. [00134] In one embodiment, a method for making a rearranged antibody light chain variable region gene sequence is provided, comprising (a) exposing a mouse as described in this disclosure to an antigen; (b) allowing the mouse to mount an immune response; (c) identifying a cell in the mouse that comprises a nucleic acid sequence that encodes a rearranged human VX domain sequence contiguous on the same nucleic acid molecule with a nucleic acid sequence encoding a mouse CK domain, wherein the cell also encodes a cognate heavy chain comprising a human VH domain and a mouse CH domain, and wherein the cell expresses an antibody that binds the antigen; (d) cloning from the cell a nucleic acids sequence encoding the human VX domain and a nucleic acid sequence 23 WO 2011/163311 PCT/US2011/041366 encoding the cognate human VH domain; and, (e) using the cloned nucleic acid sequence encoding the human VX domain and the cloned nucleic acid sequence encoding the cognate human VH domain to make a fully human antibody. [00135] In one embodiment, a method for making a rearranged antibody light chain variable region gene sequence is provided, comprising (a) exposing a mouse as described herein to an antigen; (b) allowing the mouse to mount an immune response to the antigen; (c) identifying a cell in the mouse that comprises DNA that encodes a rearranged human VX domain sequence fused with a mouse Ck domain, wherein the cell also encodes a cognate heavy chain comprising a human VH domain and a mouse CH domain, and wherein the cell expresses an antibody that binds the antigen; (d) cloning from the cell a nucleic acid sequence encoding the rearranged human VX domain and a nucleic acid sequence encoding the cognate human VH domain; and, (e) using the cloned nucleic acid sequence encoding the human Vk domain and the cloned nucleic acid sequence encoding the cognate human VH domain to make a fully human antibody. In one embodiment, the mouse C domain is mouse CX2. In a specific embodiment, the mouse CX domain is derived from a CX gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse C2. [00136] In one aspect, a genetically modified mouse is provided that expresses a human -derived light chain fused to an endogenous light chain constant region (CL), wherein the mouse, upon immunization with antigen, makes an antibody comprising a human VX domain fused to a mouse CL domain. In one embodiment, the mouse CL domain is selected from a CK domain and a CX domain. In one embodiment, the mouse CL domain is a CK domain. In one embodiment, the mouse CL domain is a C domain. In a specific embodiment, the C domain is CX2. In a specific embodiment, the mouse CX domain is derived from a CX gene that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% identical to mouse CX2. [00137] In one aspect, a genetically modified mouse comprising a modified endogenous K or X light chain locus as described herein, is provided that expresses a plurality of immunoglobulin X light chains associated with a plurality of immunoglobulin heavy chains. In one embodiment, the heavy chain comprises a human sequence. In various embodiments, the human sequence is selected from a variable sequence, a CH 1 , a hinge, a CH2, a CH3, and a combination thereof. In one embodiment, the plurality of immunoglobulin X light chains comprises a human sequence. In various embodiments, the human sequence is selected from a variable sequence, a constant sequence, and a combination thereof. In one embodiment, the mouse comprises a disabled endogenous immunoglobulin locus and expresses the heavy chain and/or the X light chain from a 24 WO 2011/163311 PCT/US2011/041366 transgene or extrachromosomal episome. In one embodiment, the mouse comprises a replacement at an endogenous mouse locus of some or all endogenous mouse heavy chain gene segments (i.e., V, D, J), and/or some or all endogenous mouse heavy chain constant sequences (e.g., CH 1 , hinge, CH 2 , CH 3 , or a combination thereof), and/or some or all endogenous mouse light chain sequences (e.g., V, J, constant, or a combination thereof), with one or more human immunoglobulin sequences. [00138] In one aspect, a mouse suitable for making antibodies that have a human X derived light chain is provided, wherein all or substantially all antibodies made in the mouse are expressed with a human k-derived light chain. In one embodiment, the human -derived light chain is expressed from an endogenous light chain locus. In one embodiment, the endogenous light chain locus is a K light chain locus. In a specific embodiment, the K light chain locus is a mouse K light chain locus. [00139] In one aspect, a method for making a -derived light chain for a human antibody is provided, comprising obtaining from a mouse as described herein a light chain sequence and a heavy chain sequence, and employing the light chain sequence and the heavy chain sequence in making a human antibody. [00140] In one aspect, a method for making an antigen-binding protein is provided, comprising exposing a mouse as described herein to an antigen; allowing the mouse to mount an immune response; and obtaining from the mouse an antigen-binding protein that binds the antigen, or obtaining from the mouse a sequence to be employed in making an antigen-binding protein that binds the antigen. [00141] In one aspect, a cell derived from a mouse as described herein is provided. In one embodiment, the cell is selected from an embryonic stem cell, a pluripotent cell, an induced pluripotent cell, a B cell, and a hybridoma. [00142] In one aspect, a cell is provided that comprises a genetic modification as described herein. In one embodiment, the cell is a mouse cell. In one embodiment, the cell is selected from a hybridoma and a quadroma. In one embodiment, the cell expresses an immunoglobulin light chain that comprises a human k variable sequence fused with a mouse constant sequence. In a specific embodiment, the mouse constant sequence is a mouse K constant sequence. [00143] In one aspect, a tissue derived from a mouse as described herein is provided. [00144] In one aspect, use of a mouse or a cell as described herein to make an antigen binding protein is provided. In one embodiment, the antigen-binding protein is a human protein. In one embodiment, the human protein is a human antibody. 25 WO 2011/163311 PCT/US2011/041366 [00145] In one aspect, an antigen-binding protein made by a mouse, cell, tissue, or method as described herein is provided. In one embodiment, the antigen-binding protein is a human protein. In one embodiment, the human protein is a human antibody. [00146] Any of the embodiments and aspects described herein can be used in conjunction with one another, unless otherwise indicated or apparent from the context. Other embodiments will become apparent to those skilled in the art from a review of the ensuing description. BRIEF DESCRIPTION OF THE FIGURES [00147] FIG. 1 shows a detailed illustration, not to scale, of the human k light chain locus including the clusters of VX gene segments (A, B and C) and the JX and Ck region pairs (J-C pairs) [00148] FIG. 2 shows a general illustration, not to scale, of a targeting strategy used to inactivate the endogenous mouse k light chain locus. [00149] FIG. 3 shows a general illustration, not to scale, of a targeting strategy used to inactivate the endogenous mouse K light chain locus. [00150] FIG. 4A shows a general illustration, not to scale of an initial targeting vector for targeting the endogenous mouse k light chain locus with human k light chain sequences including 12 hVk gene segments and hJk1 gene segment (12/1-k Targeting Vector). [00151] FIG. 4B shows a general illustration, not to scale, of four initial targeting vectors for targeting the endogenous mouse K light chain locus with human K light chain sequences including 12 hVk gene segments and hJk1 gene segment (1 2 /1-K Targeting Vector), 12 hVk gene segments and hJk1, 2, 3 and 7 gene segments (12/ 4 -K Targeting Vector), 12 hVk gene segments, a human VK-JK genomic sequence and hJk1 gene segment (1 2 (K)1-K Targeting Vector) and 12 hVk gene segments, a human VK-JK genomic sequence and hJk1, 2, 3 and 7 gene segments (1 2
(K)
4 -K Targeting Vector). [00152] FIG. 5A shows a general illustration, not to scale, of a targeting strategy for progressive insertion of 40 hVk gene segments and a single hJk gene segment into the mouse k light chain locus. [00153] FIG. 5B shows a general illustration, not to scale, of a targeting strategy for progressive insertion of 40 hVX gene segments and a single hJk gene segment into the mouse K locus. [00154] FIG. 6 show a general illustration, not to scale, of the targeting and molecular engineering steps employed to make unique human K-K hybrid targeting vectors for construction of a hybrid light chain locus containing a human K intergenic sequence, multiple hJK gene segments or both. 26 WO 2011/163311 PCT/US2011/041366 [00155] FIG. 7A shows a general illustration, not to scale, of the locus structure for a modified mouse k light chain locus containing 40 hVk gene segments and a single hJR gene segment operably linked to the endogenous C2 gene. [00156] FIG. 7B shows a general illustration, not to scale, of the locus structure for four independent, modified mouse K light chain loci containing 40 hVk gene segments and either one or four hJR gene segments with or without a contiguous human VK-JK genomic sequence operably linked to the endogenous CK gene. [00157] FIG. 8A shows contour plots of lgk* and Igx* splenocytes gated on CD19* from a wild type mouse (WT), a mouse homozygous for 12 hVk and four hJR gene segments including a human Vw-JK genomic sequence (12hVk-VwJK-4hJk) and a mouse homozygous for 40 hVk and one hJR gene segment (40hVk-1 hJ). [00158] FIG. 8B shows the total number of CD19* B cells in harvested spleens from wild type (WT), mice homozygous for 12 hVk and four hJR gene segments including a human Vx-Jx genomic sequence (1 2hVk-VwJK-4hJk) and mice homozygous for 40 hVk and one hJR gene segment (40hVk-1 hJ). [00159] FIG. 9A, in the top panel, shows contour plots of splenocytes gated on singlets and stained for B and T cells (CD19' and CD3*, respectively) from a wild type mouse (WT) and a mouse homozygous for 40 hVk and four JR gene segments including a human Vx-Jw genomic sequence (40hVk-VxJK-4hJR). The bottom panel shows contour plots of splenocytes gated on CD19* and stained for lgk* and Igx* expression from a wild type mouse (WT) and a mouse homozygous for 40 hVk and four JR gene segments including a human Vx-Jx genomic sequence (40hVk-VxJK-4hJk). [00160] FIG. 9B shows the total number of CD19*, CD19*Igx* and CD19*lgk* B cells in harvested spleens from wild type mice (WT) and mice homozygous for 40 hVX and four JR gene segments including a human VK-Jx genomic sequence (40hVk-VKJK-4hJk). [00161] FIG. 9C shows contour plots of splenocytes gated on CD19* and stained for immunoglobulin D (IgD) and immunoglobulin M (IgM) from a wild type mouse (WT) and a mouse homozygous for 40 hVX and four JR gene segments including a human Vx-Jx genomic sequence (40hVk-VxJK-4hJR). Mature (72 for WT, 51 for 40hVk-VKJx-4hJk) and transitional (13 for WT, 22 for 40hVk-VxJx-4hJ?) B cells are noted on each of the contour plots. [00162] FIG. 9D shows the total number of CD19* B cells, transitional B cells (CD19+IgMh gD'O) and mature B cells (CD19'IgM'IgDhi) in harvested spleens from wild type mice (WT) and mice homozygous for 40 hV and four JR gene segments including a human VK-JK genomic sequence (40hVk-VKJK-4hJk). 27 WO 2011/163311 PCT/US2011/041366 [00163] FIG. 10A, in the top panel, shows contour plots of bone marrow stained for B and T cells (CD19* and CD3*, respectively) from a wild type mouse (WT) and a mouse homozygous for 40 hVk and four JX gene segments including a human VK-JK genomic sequence (40hVk-VKJK-4hJk). The bottom panel shows contour plots of bone marrow gated on CD19* and stained for ckit* and CD43' from a wild type mouse (WT) and a mouse homozygous for 40 hVk and four JX gene segments including a human VK-JK genomic sequence (40hV-VKJK-4hJk). Pro and Pre B cells are noted on the contour plots of the bottom panel. [00164] FIG. 1OB shows the number of Pro (CD19*CD43*ckit*) and Pre (CD19*CD43 ckit~) B cells in bone marrow harvested from the femurs of wild type mice (WT) and mice homozygous for 40 hV and four JX gene segments including a human Vi-JK genomic sequence (40hVk-VKJK-4hJk). [00165] FIG. 10C shows contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a wild type mouse (WT) and a mouse homozygous for 40 hVk and four JX gene segments including a human Vx-JK genomic sequence (40hVk-VKJK-4hJk). Immature, mature and pro/pre B cells are noted on each of the contour plots. [00166] FIG. 10D shows the total number of immature (B220ntgM*) and mature (B220hilgM*) B cells in bone marrow isolated from the femurs of wild type mice (WT) and mice homozygous for 40 hVk and four JX gene segments including a human VK-JK genomic sequence (40hVX-VKJK-4hJk). [00167] FIG. 10E shows contour plots of bone marrow gated on immature (B220'ntlgM+) and mature (B220hIgM+) B cells stained for Igk and IgK expression isolated from the femurs of a wild type mouse (WT) and a mouse homozygous for 40 hVk and four JX gene segments including a human VK-JK genomic sequence (40hVk-VKJK-4hJk). [00168] FIG. 11 shows a nucleotide sequence alignment of the VX-JX-CK junction of eighteen independent RT-PCR clones amplified from splenocyte RNA of mice bearing human % light chain gene sequences at an endogenous mouse K light chain locus. A6 = SEQ ID NO:57; B6 = SEQ ID NO:58; F6 = SEQ ID NO:59; B7 = SEQ ID NO:60; E7 = SEQ ID NO:61; F7 = SEQ ID NO:62; C8 = SEQ ID NO:63; E12 = SEQ ID NO:64; 1-4 = SEQ ID NO:65; 1-20 = SEQ ID NO:66; 3B43 = SEQ ID NO:67; 5-8 = SEQ ID NO:68; 5-19 = SEQ ID NO:69; 1010 = SEQ ID NO:70; 11A1 = SEQ ID NO:71; 7A8 = SEQ ID NO:72; 3A3 = SEQ ID NO:73; 2-7 = SEQ ID NO:74. Lower case bases indicate non-germline bases resulting from either mutation and/or N addition during recombination. Consensus amino acids within the Framework 4 region (FWR4) encoded by the nucleotide sequence of hJk1 and mouse CK are noted at the bottom of the sequence alignment. 28 WO 2011/163311 PCT/US2011/041366 [00169] FIG. 12 shows a nucleotide sequence alignment of the VX-JX-CK junction of twelve independent RT-PCR clones amplified from splenocyte RNA of mice bearing human k light chain gene sequences including a contiguous human VK-JK genomic sequence at an endogenous mouse K light chain locus. 5-2 = SEQ ID NO:87; 2-5 = SEQ ID NO:88; 1-3 = SEQ ID NO:89; 4B-1 = SEQ ID NO:90; 3B-5 = SEQ ID NO:91; 7A-1 = SEQ ID NO:92; 5 1 = SEQ ID NO:93; 4A-1 = SEQ ID NO:94; 1 1A-1 = SEQ ID NO:95; 5-7 = SEQ ID NO:96; 5-4 = SEQ ID NO:97; 2-3 = SEQ ID NO:98. Lower case bases indicate non-germline bases resulting from either mutation and/or N addition during recombination. Consensus amino acids within the Framework 4 region (FWR4) encoded by the nucleotide sequence of each human JX and mouse CK are noted at the bottom of the sequence alignment. [00170] FIG. 13 shows a nucleotide sequence alignment of the VX-JX-CX junction of three independent RT-PCR clones amplified from splenocyte RNA of mice bearing human X light chain gene sequences at an endogenous mouse X light chain locus. 2D1 = SEQ ID NO:101; 2D9 = SEQ ID NO:102; 3E15 = SEQ ID NO:103. Lower case bases indicate non-germline bases resulting from either mutation and/or N addition during recombination. Consensus amino acids within the Framework 4 region (FWR4) encoded by the nucleotide sequence of hJk1 and mouse C2 are noted at the bottom of the sequence alignment. DETAILED DESCRIPTION [00171] Although specific features of various embodiments are discussed in detail, the descriptions of the specific aspects, embodiments, and examples do not limit the subject matter of the claims; it is the claims that describe the scope of the invention. All terms and phrases used in this disclosure include the meanings normally ascribed to them in the art. [00172] The term "contiguous" includes reference to occurrence on the same nucleic acid molecule, e.g., two nucleic acid sequences are "contiguous" if they occur on the same nucleic molecule but are interrupted by another nucleic acid sequence. For example, a rearranged V(D)J sequence is "contiguous" with a constant region gene sequence, although the final codon of the V(D)J sequence is not followed immediately by the first codon of the constant region sequence. In another example, two V gene segment sequences are "contiguous" if they occur on the same genomic fragment, although they may be separated by sequence that does not encode a codon of the V region, e.g., they may be separated by a regulatory sequence, e.g., a promoter or other noncoding sequence. In one embodiment, a contiguous sequence includes a genomic fragment that contains genomic sequences arranged as found in a wild-type genome. [00173] The phrase "derived from" when used concerning a variable region "derived from" a cited gene or gene segment includes the ability to trace the sequence back to a 29 WO 2011/163311 PCT/US2011/041366 particular unrearranged gene segment or gene segments that were rearranged to form a gene that expresses the variable domain (accounting for, where applicable, splice differences and somatic mutations). [00174] The phrase "functional" when used concerning a variable region gene segment or joining gene segment refers to usage in an expressed antibody repertoire; e.g., in humans V gene segments 3-1, 4-3, 2-8, etc. are functional, whereas V gene segments 3-2, 3-4, 2-5, etc. are nonfunctional. [00175] A "heavy chain locus" includes a location on a chromosome, e.g., a mouse chromosome, wherein in a wild-type mouse heavy chain variable (VH) , heavy chain diversity (DH), heavy chain joining (JH), and heavy chain constant (CH) region DNA sequences are found. [00176] A "c locus" includes a location on a chromosome, e.g., a mouse chromosome, wherein in a wild-type mouse Kvariable (V), K joining (JK), and K constant (CK) region DNA sequences are found. [00177] A "k locus" includes a location on a chromosome, e.g., a mouse chromosome, wherein in a wild-type mouse A variable (V), k joining (JX), and X constant (Ck) region DNA sequences are found. [00178] The term "unrearranged" includes the state of an immunoglobulin locus wherein V gene segments and J gene segments (for heavy chains, D gene segments as well) are maintained separately but are capable of being joined to form a rearranged V(D)J gene that comprises a single V,(D),J of the V(D)J repertoire. Mice Expressing Human X Variable Domains [00179] Mice that express antibodies that are fully human, or partly human and partly mouse, have previously been reported. VELOCIMMUNE@ genetically engineered mice comprise a replacement of unrearranged V(D)J gene segments at endogenous mouse loci with human V(D)J gene segments. VELOCIMMUNE@ mice express chimeric antibodies having human variable domains and mouse constant domains (see, e.g., US Pat. No. 7,605,237). Most other reports concern mice that express fully human antibodies from fully human transgenes in mice that have disabled endogenous immunoglobulin loci. [00180] Antibody light chains are encoded by one of two separate loci: kappa (K) and lambda (Q). Mouse antibody light chains are primarily of the K type. Mice that make mouse antibodies, and modified mice that make fully human or chimeric human-mouse antibodies, display a bias in light chain usage. Humans also exhibit light chain bias, but not so pronounced as in mice; the ratio of K light chains to X light chains in mice is about 95:5, whereas in humans the ratio is about 60:40. The more pronounced bias in mice is 30 WO 2011/163311 PCT/US2011/041366 not thought to severely affect antibody diversity, because in mice the X variable locus is not so diverse in the first instance. This is not so in humans. The human k light chain locus is richly diverse. [00181] The human k light chain locus extends over 1,000 kb and contains over 80 genes that encode variable (V) or joining (J) segments (FIG. 1). Within the human k light chain locus, over half of all observed VX domains are encoded by the gene segments 1-40, 1-44, 2-8, 2-14, and 3-21. Overall, about 30 or so of the human VX gene segments are believed to be functional. There are seven JX gene segments, only four of which are regarded as generally functional JX gene segments-Jk1, Jk2, Jk3, and JR7. [00182] The k light chain locus in humans is similar in structure to the K locus of both mice and humans in that the human k light chain locus has several variable region gene segments that are capable of recombining to form a functional light chain protein. The human k light chain locus contains approximately 70 V gene segments and 7 JX-CX gene segment pairs. Only four of these JX-CX gene segment pairs appear to be functional. In some alleles, a fifth JX-CX gene segment pair is reportedly a pseudo gene (C6). The 70 VX gene segments appear to contain 38 functional gene segments. The 70 Vk sequences are arranged in three clusters, all of which contain different members of distinct V gene family groups (clusters A, B and C; FIG. 1). This is a potentially rich source of relatively untapped diversity for generating antibodies with human V regions in non-human animals. [00183] In stark contrast, the mouse k light chain locus contains only two or three (depending on the strain) mouse VX region gene segments (FIG. 2). At least for this reason, the severe K bias in mice is not thought to be particularly detrimental to total antibody diversity. [00184] According published maps of the mouse k light chain locus, the locus consists essentially of two clusters of gene segments within a span of approximately 200 kb (FIG.2). The two clusters contain two sets of V, J, and C genes that are capable of independent rearrangement: Vk2-JR2-Ck2-JR4-Ck4 and V1 -JR3-Ck3-J1 -C1. Although VX2 has been found to recombine with all JR gene segments, VX1 appears to exclusively recombine with CU1. C4 is believed to be a pseudo gene with defective splice sites. [00185] The mouse K light chain locus is strikingly different. The structure and number of gene segments that participate in the recombination events leading to a functional light chain protein from the mouse K locus is much more complex (FIG. 3). Thus, mouse k light chains do not greatly contribute to the diversity of an antibody population in a typical mouse. 31 WO 2011/163311 PCT/US2011/041366 [00186] Exploiting the rich diversity of the human k light chain locus in mice would likely result in, among other things, a source for a more complete human repertoire of light chain V domains. Previous attempts to tap this diversity used human transgenes containing chunks of the human k light chain locus randomly incorporated into the mouse genome (see, e.g., US 6,998,514 and US 7,435,871). Mice containing these randomly integrated transgenes reportedly express fully human k light chains, however, in some cases, one or both endogenous light chain loci remain intact. This situation is not desirable as the human k light chain sequences contend with the mouse light chain (x or k) in the expressed antibody repertoire of the mouse. [00187] In contrast, the inventors describe genetically modified mice that are capable of expressing one or more X light chain nucleic acid sequences directly from a mouse light chain locus, including by replacement at an endogenous mouse light chain locus. Genetically modified mice capable of expressing human k light chain sequences from an endogenous locus may be further bred to mice that comprise a human heavy chain locus and thus be used to express antibodies comprising V regions (heavy and light) that are fully human. In various embodiments. The V regions express with mouse constant regions. In various embodiments, no endogenous mouse immunoglobulin gene segments are present and the V regions express with human constant regions. These antibodies would prove useful in numerous applications, both diagnostic as well as therapeutic. [00188] Many advantages can be realized for various embodiments of expressing binding proteins derived from human VX and JR gene segments in mice. Advantages can be realized by placing human k sequences at an endogenous light chain locus, for example, the mouse K or k locus. Antibodies made from such mice can have light chains that comprise human Vk domains fused to a mouse CL region, specifically a mouse CK or Ck region. The mice will also express human VX domains that are suitable for identification and cloning for use with human CL regions, specifically CK and/or Ck regions. Because B cell development in such mice is otherwise normal, it is possible to generate compatible Vk domains (including somatically mutated VA domains) in the context of either Ck or CK regions. [00189] Genetically modified mice are described that comprise an unrearranged Vk gene segment at an immunoglobulin K or k light chain locus. Mice that express antibodies that comprise a light chain having a human Vk domain fused to a CK and/or Ck region are described. 32 WO 2011/163311 PCT/US2011/041366 Sterile Transcripts of the Immunoglobulin K Light Chain Locus [00190] Variations on the theme of expressing human immunoglobulin k sequences in mice are reflected in various embodiments of genetically modified mice capable of such expression. Thus, in some embodiments, the genetically modified mice comprise certain non-coding sequence(s) from a human locus. In one embodiment, the genetically modified mouse comprises human Vk and Jk gene segments at an endogenous K light chain locus, and further comprises a human K light chain genomic fragment. In a specific embodiment, the human K light chain genomic fragment is a non-coding sequence naturally found between a human VK gene segment and a human JK gene segment. [00191] The human and mouse K light chain loci contain sequences that encode sterile transcripts that lack either a start codon or an open reading frame, and that are regarded as elements that regulate transcription of the K light chain loci. These sterile transcripts arise from an intergenic sequence located downstream or 3' of the most proximal VK gene segment and upstream or 5' of the K light chain intronic enhancer (EKi) that is upstream of the K light chain constant region gene (CK). The sterile transcripts arise from rearrangement of the intergenic sequence to form a VKJK1 segment fused to a CK. [00192] A replacement of the K light chain locus upstream of the CK gene would remove the intergenic region encoding the sterile transcripts. Therefore, in various embodiments, a replacement of mouse K light chain sequence upstream of the mouse CK gene with human k light chain gene segments would result in a humanized mouse K light chain locus that contains human VX and Jk gene segments but not the K light chain intergenic region that encodes the sterile transcripts. [00193] As described herein, humanization of the endogenous mouse K light chain locus with human k light chain gene segments, wherein the humanization removes the intergenic region, results in a striking drop in usage of the K light chain locus, coupled with a marked increase in k light chain usage. Therefore, although a humanized mouse that lacks the intergenic region is useful in that it can make antibodies with human light chain variable domains (e.g., human k or K domains), usage from the locus decreases. [00194] Also described is humanization of the endogenous mouse K light chain locus with human Vk and Jk gene segments coupled with an insertion of a human K intergenic region to create a VK locus that contains, with respect to transcription, between the final human Vk gene segment and the first human JK gene segment, a K intergenic region; which exhibits a B cell population with a higher expression than a locus that lacks the K intergenic region. This observation is consistent with a hypothesis that the intergenic region-directly through a sterile transcript, or indirectly-suppresses usage from the 33 WO 2011/163311 PCT/US2011/041366 endogenous X light chain locus. Under such a hypothesis, including the intergenic region would result in a decrease in usage of the endogenous k light chain locus, leaving the mouse a restricted choice but to employ the modified (K into K) locus to generate antibodies. [00195] In various embodiments, a replacement of mouse K light chain sequence upstream of the mouse C gene with human k light chain sequence further comprises a human K light chain intergenic region disposed, with respect to transcription, between the 3' untranslated region of the 3' most Vk gene segment and 5' to the first human Jk gene segment. Alternatively, such an intergenic region may be omitted from a replaced endogenous K light chain locus (upstream of the mouse Cx gene) by making a deletion in the endogenous k light chain locus. Likewise, under this embodiment, the mouse generates antibodies from an endogenous K light chain locus containing human k light chain sequences. Approaches to Engineering Mice to Express Human VX Domains [00196] Various approaches to making genetically modified mice that make antibodies that contain a light chain that has a human Vk domain fused to an endogenous CL (e.g. OK or Ck) region are described. Genetic modifications are described that, in various embodiments, comprise a deletion of one or both endogenous light chain loci. For example, to eliminate mouse K light chains from the endogenous antibody repertoire a deletion of a first Vk-JK-Ck gene cluster and replacement, in whole or in part, of the Vk-JK gene segments of a second gene cluster with human Vk-JK gene segments can be made. Genetically modified mouse embryos, cells, and targeting constructs for making the mice, mouse embryos, and cells are also provided. [00197] The deletion of one endogenous VK-JK-CK gene cluster and replacement of the Vk-JK gene segments of another endogenous VK-JK-Ck gene cluster employs a relatively minimal disruption in natural antibody constant region association and function in the animal, in various embodiments, because endogenous Ck genes are left intact and therefore retain normal functionality and capability to associate with the constant region of an endogenous heavy chain. Thus, in such embodiments the modification does not affect other endogenous heavy chain constant regions dependent upon functional light chain constant regions for assembly of a functional antibody molecule containing two heavy chains and two light chains. Further, in various embodiments the modification does not affect the assembly of a functional membrane-bound antibody molecule involving an endogenous heavy chain and a light chain, e.g., a hVK domain linked to a mouse CK region. Because at least one functional CK gene is retained at the endogenous locus, 34 WO 2011/163311 PCT/US2011/041366 animals containing a replacement of the VX-JX gene segments of an endogenous VX-JX Ck gene cluster with human Vk-JR gene segments should be able to make normal k light chains that are capable of binding antigen during an immune response through the human Vk-JR gene segments present in the expressed antibody repertoire of the animal. [00198] A schematic illustration (not to scale) of a deleted endogenous mouse Vk-JR-Ck gene cluster is provided in FIG. 2. As illustrated, the mouse k light chain locus is organized into two gene clusters, both of which contain function gene segments capable of recombining to form a function mouse k light chain. The endogenous mouse Vk1-JR3-Ck3 JR1-Ck1 gene cluster is deleted by a targeting construct (Targeting Vector 1) with a neomycin cassette flanked by recombination sites. The other endogenous gene cluster (Vk2-V3-JX2-CX2-Jk4-C4) is deleted in part by a targeting construct (Targeting Vector 2) with a hygromycin-thymidine kinase cassette flanked by recombination sites. In this second targeting event, the Ck2-JR4-Ck4 endogenous gene segments are retained. The second targeting construct (Targeting Vector 2) is constructed using recombination sites that are different than those in the first targeting construct (Targeting Vector 1) thereby allowing for the selective deletion of the selection cassette after a successful targeting has been achieved. The resulting double-targeted locus is functionally silenced in that no endogenous k light chain can be produced. This modified locus can be used for the insertion of human Vk and JR gene segments to create an endogenous mouse k locus comprising human Vk and JR gene segments, whereby, upon recombination at the modified locus, the animal produces k light chains comprising rearranged human Vk and JR gene segments linked to an endogenous mouse Ck gene segment. [00199] Genetically modifying a mouse to render endogenous k gene segments nonfunctional, in various embodiments, results in a mouse that exhibits exclusively K light chains in its antibody repertoire, making the mouse useful for evaluating the role of k light chains in the immune response, and useful for making an antibody repertoire comprising Vx domains but not Vk domains. [00200] A genetically modified mouse that expresses a hVk linked to a mouse Ck gene having been recombined at the endogenous mouse k light chain locus can be made by any method known in the art. A schematic illustration (not to scale) of the replacement of the endogenous mouse VX2-VX3-JX2 gene segments with human VX and JR gene segments is provided in FIG. 4A. As illustrated, an endogenous mouse k light chain locus that had been rendered nonfunctional is replaced by a targeting construct (12/1-k Targeting Vector) that includes a neomycin cassette flanked by recombination sites. The Vk2-VX3-Jk2 gene 35 WO 2011/163311 PCT/US2011/041366 segments are replaced with a genomic fragment containing human k sequence that includes 12 hVk gene segments and a single hJ gene segment. [00201] Thus, this first approach positions one or more hVk gene segments at the endogenous k light chain locus contiguous with a single hJR gene segment (FIG. 4A). [00202] Further modifications to the modified endogenous k light chain locus can be achieved with using similar techniques to insert more hVk gene segments. For example, schematic illustrations of two additional targeting constructs (+1 6-X and +1 2-X Targeting Vectors) used for progressive insertion of addition human hVk gene segments are provided in FIG. 5A. As illustrated, additional genomic fragments containing specific human hVk gene segments are inserted into the modified endogenous k light chain locus in successive steps using homology provided by the previous insertion of human k light chain sequences. Upon recombination with each targeting construct illustrated, in sequential fashion, 28 additional hVk gene segments are inserted into the modified endogenous k light chain locus. This creates a chimeric locus that produces a k light chain protein that comprises human Vk-Jk gene segments linked to a mouse Ck gene. [00203] The above approaches to insert human k light chain gene segments at the mouse k locus, maintains the enhancers positioned downstream of the Ck2-Jk4-Ck4 gene segments (designated Enh 2.4, Enh and Enh 3.1 FIG. 4A and FIG. 5A). This approach results in a single modified allele at the endogenous mouse k light chain locus (FIG. 7A). [00204] Compositions and methods for making a mouse that expresses a light chain comprising hVk and JR gene segments operably linked to a mouse CX gene segment, are provided, including compositions and method for making a mouse that expresses such genes from an endogenous mouse k light chain locus. The methods include selectively rendering one endogenous mouse Vk-Jk-Ck gene cluster nonfunctional (e.g., by a targeted deletion), and employing a hVk and JR gene segments at the endogenous mouse k light chain locus to express a hVk domain in a mouse. [00205] Alternatively, in a second approach, human k light chain gene segments may be positioned at the endogenous K light chain locus. The genetic modification, in various embodiments, comprises a deletion of the endogenous K light chain locus. For example, to eliminate mouse K light chains from the endogenous antibody repertoire a deletion of the mouse VK and JK gene segments can be made. Genetically modified mouse embryos, cells, and targeting constructs for making the mice, mouse embryos, and cells are also provided. [00206] For the reasons stated above, the deletion of the mouse VK and JK gene segments employs a relatively minimal disruption. A schematic illustration (not to scale) of 36 WO 2011/163311 PCT/US2011/041366 deleted mouse VK and JK gene segments is provided in FIG. 3. The endogenous mouse VK and JK gene segments are deleted via recombinase-mediated deletion of mouse sequences position between two precisely positioned targeting vectors each employing site-specific recombination sites. A first targeting vector (JK Targeting Vector) is employed in a first targeting event to delete the mouse JR gene segments. A second targeting vector (Vx Targeting Vector) is employed in a second, sequential targeting event to delete a sequence located 5' of the most distal mouse VK gene segment. Both targeting vectors contain site-specific recombination sites thereby allowing for the selective deletion of both selection cassettes and all intervening mouse K light chain sequences after a successful targeting has been achieved. The resulting deleted locus is functionally silenced in that no endogenous K light chain can be produced. This modified locus can be used for the insertion of hVk and JX gene segments to create an endogenous mouse K locus comprising hVk and JX gene segments, whereby, upon recombination at the modified locus, the animal produces k light chains comprising rearranged hVk and JR gene segments operably linked to an endogenous mouse CK gene segment. Various targeting vectors comprising human X light chain sequences can be used in conjunction with this deleted mouse K locus to create a hybrid light chain locus containing human k gene segments operably linked with a mouse CK region. [00207] Thus, a second approach positions one or more human V? gene segments are positioned at the mouse K light chain locus contiguous with a single human JX gene segment (1 2 /1-K Targeting Vector, FIG. 4B). [00208] In various embodiments, modifications to this approach can be made to add gene segments and/or regulatory sequences to optimize the usage of the human X light chain sequences from the mouse K locus within the mouse antibody repertoire. [00209] In a third approach, one or more hV gene segments are positioned at the mouse i light chain locus contiguous with four hJR gene sequences (12/4-K Targeting Vector FIG. 4B). [00210] In a third approach, one or more hVk gene segments are positioned at the mouse K light chain locus contiguous with a human K intergenic sequence and a single hJR gene sequence (1 2 (K)1-K Targeting Vector, FIG. 4B). [00211] In a fourth approach, one or more hVk gene segments are positioned at the mouse K light chain locus contiguous with a human K intergenic sequence four hJR gene sequences (12(x)4-x Targeting Vector FIG. 4B). [00212] All of the above approaches to insert human ? light chain gene segments at the mouse K locus, maintain the K intronic enhancer element upstream of the CK gene 37 WO 2011/163311 PCT/US2011/041366 (designated Exi, FIG. 4B and FIG. 5B) and the 3' ic enhancer downstream of the CK gene (designated EK3', FIG. 4B and FIG. 5B). The approaches result in four separate modified alleles at the endogenous mouse K light chain locus (FIG. 7B). [00213] In various embodiments, genetically modified mouse comprise a knockout of the endogenous mouse X light chain locus. In one embodiment, the k light chain locus is knocked out by a strategy that deletes the region spanning Vk2 to Jk2, and the region spanning Vk1 to C1 (FIG. 2). Any strategy that reduces or eliminates the ability of the endogenous k light chain locus to express endogenous k domains is suitable for use with embodiments in this disclosure. Lambda Domain Antibodies from Genetically Modified Mice [00214] Mice comprising human k sequences at either the mouse K or k light chain locus will express a light chain that comprises a hVK region fused to a mouse CL (CK or Ck) region. These are advantageously bred to mice that (a) comprise a functionally silenced light chain locus (e.g., a knockout of the endogenous mouse K or k light chain locus); (b) comprise an endogenous mouse k light chain locus that comprises hV and hJ gene segments operably linked to an endogenous mouse Ck gene; (c) comprise an endogenous mouse K light chain locus that comprises hVK and hJK gene segments operably linked to an endogenous mouse CK gene; and, (d) a mouse in which one K allele comprises hVKs and hJKs; the other K allele comprising hVks and hJs; one k allele comprising hVks and hJs and one k allele silenced or knocked out, or both k alleles comprising hVks and hJXs; and, two heavy chain alleles that each comprise hVHs, hDHs, and hJHs [00215] The antibodies that comprise the hVX domains expressed in the context of either CK or CX are used to make fully human antibodies by cloning the nucleic acids encoding the hVX domains into expression constructs that bear genes encoding human Ck. Resulting expression constructs are transfected into suitable host cells for expressing antibodies that display a fully hVX domain fused to hC. EXAMPLES [00216] The following examples are provided so as to describe how to make and use methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Unless indicated otherwise, temperature is indicated in Celsius, and pressure is at or near atmospheric. 38 WO 2011/163311 PCT/US2011/041366 Example I Deletion of the Mouse Immunoglobulin Light Chain Loci [00217] Various targeting constructs were made using VELOCIGENE@ technology (see, e.g., US Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nature Biotech. 21(6):652-659) to modify mouse genomic Bacterial Artificial Chromosome (BAC) libraries to inactivate the mouse K and k light chain loci. [00218] Deletion of the mouse % light chain locus. DNA from mouse BAC clone RP23-135k1 5 (Invitrogen) was modified by homologous recombination to inactivate the endogenous mouse k light chain locus through targeted deletion of the VX-JX-CX gene clusters (FIG. 2). [00219] Briefly, the entire proximal cluster comprising Vk1-Jk3-Ck3-JR1-Ck1 gene segments was deleted in a single targeting event using a targeting vector comprising a neomycin cassette flanked by loxP sites with a 5' mouse homology arm containing sequence 5' of the VX1 gene segment and a 3' mouse homology arm containing sequence 3' of the C1 gene segment (FIG. 2, Targeting Vector 1). [00220] A second targeting construct was prepared to precisely delete the distal endogenous mouse k gene cluster containing VX2-Jk2-CX2-JR4-Ck4 except that the targeting construct contained a 5' mouse homology arm that contained sequence 5' of the V2 gene segment and a 3' mouse homology arm that contained sequence 5' to the endogenous Ck2 gene segment (FIG. 2, Targeting Vector 2). Thus, the second targeting construct precisely deleted Vk2-JX2, while leaving CX2-Jk4-Ck4 intact at the endogenous mouse k locus. ES cells containing an inactivated endogenous X locus (as described above) were confirmed by karyotyping and screening methods (e.g., TAQMAN@) known in the art. DNA was then isolated from the modified ES cells and subjected to treatment with CRE recombinase thereby mediating the deletion of the proximal targeting cassette containing the neomycin marker gene, leaving only a single loxP site at the deletion point (FIG. 2, bottom). [00221] Deletion of the mouse K light chain locus. Several targeting constructs were made using similar methods described above to modify DNA from mouse BAC clones RP23-302g12 and RP23-254m04 (Invitrogen) by homologous recombination to inactivate the mouse K light chain locus in a two-step process (FIG. 3). [00222] Briefly, the JK gene segments (1-5) of the endogenous mouse K light chain locus were deleted in a single targeting event using a targeting vector comprising a hygromycin-thymidine kinase (hyg-TK) cassette containing a single loxP site 3' to the hyg TK cassette (FIG. 3, J Targeting Vector). The homology arms used to make this targeting 39 WO 2011/163311 PCT/US2011/041366 vector contained mouse genomic sequence 5' and 3' of the endogenous mouse Jx gene segments. In a second targeting event, a second targeting vector was prepared to delete a portion of mouse genomic sequence upstream (5') to the most distal endogenous mouse VK gene segment (FIG. 3, VK Targeting Vector). This targeting vector contained an inverted lox511 site, a loxP site and a neomycin cassette. The homology arms used to make this targeting vector contained mouse genomic sequence upstream of the most distal mouse Vx gene segment. The targeting vectors were used in a sequential fashion (i.e., JK then VK) to target DNA in ES cells. ES bearing a double-targeted chromosome (i.e., a single endogenous mouse K locus targeted with both targeting vectors) were confirmed by karyotyping and screening methods (e.g., Taqman T M ) known in the art. DNA was then isolated from the modified ES cells and subjected to treatment with Cre recombinase thereby mediating the deletion of endogenous mouse VK gene segments and both selection cassettes, while leaving two juxtaposed lox sites in opposite orientation relative to one another (FIG. 3, bottom; SEQ ID NO:1). [00223] Thus, two modified endogenous light chain loci (K and X) containing intact enhancer and constant regions were created for progressively inserting unrearranged human X germline gene segments in a precise manner using targeting vectors described below. Example Il Replacement of Mouse Light Chain Loci with a Human X Light Chain Mini-Locus [00224] Multiple targeting vectors were engineered for progressive insertion of human X gene segments into the endogenous mouse K and k light chain loci using similar methods as described above. Multiple independent initial modifications were made to the endogenous light chain loci each producing a chimeric light chain locus containing hVX and JX gene segments operably linked to mouse light chain constant genes and enhancers. [00225] A human X mini-locus containing 12 human VX and one human JX gene segment. A series of initial targeting vectors were engineered to contain the first 12 consecutive human VX gene segments from cluster A and a hJk1 gene segment or four hJk gene segments using a human BAC clone named RP1 1-729g4 (Invitrogen). FIGs. 4A and 4B show the targeting vectors that were constructed for making an initial insertion of human k light chain gene segments at the mouse k and K light chain loci, respectively. [00226] For a first set of initial targeting vectors, a 124,125 bp DNA fragment from the 729g4 BAC clone containing 12 hVk gene segments and a hJk1 gene segment was engineered to contain a PI-Scel site 996 bp downstream (3') of the hJk1 gene segment for 40 WO 2011/163311 PCT/US2011/041366 ligation of a 3' mouse homology arm. Two different sets of homology arms were used for ligation to this human fragment; one set of homology arms contained endogenous mouse k sequences from the 135k15 BAC clone (FIG.4A) and another set contained endogenous K sequence 5' and 3' of the mouse VK and JK gene segments from mouse BAC clones RP23-302g12 and RP23-254m04, respectively (FIG. 4B). [00227] For the 12/1-X Targeting Vector (FIG. 4A), a PI-Scel site was engineered at the 5' end of a 27,847 bp DNA fragment containing the mouse C2-Jk4-C4 and enhancer 2.4 of the modified mouse k locus described in Example 1. The -28 kb mouse fragment was used as a 3' homology arm by ligation to the -124 kb human k fragment, which created a 3' junction containing, from 5' to 3', a hJR1 gene segment, 996 bp of human k sequence 3' of the hJR1 gene segment, 1229 bp of mouse k sequence 5' to the mouse C2 gene, the mouse Ck2 gene and the remaining portion of the -28 kb mouse fragment. Upstream (5') from the human Vk3-12 gene segment was an additional 1456 bp of human k sequence before the start of the 5' mouse homology arm, which contained 23,792 bp of mouse genomic DNA corresponding to sequence 5' of the endogenous mouse X locus. Between the 5' homology arm and the beginning of the human k sequence was a neomycin cassette flanked by Frt sites. [00228] Thus, the 12/1-X Targeting Vector included, from 5' to 3', a 5' homology arm containing -24 kb of mouse k genomic sequence 5' of the endogenous k locus, a 5' Frt site, a neomycin cassette, a 3' Frt site, -123 kb of human genomic k sequence containing the first 12 consecutive hVk gene segments and a hJR1 gene segment, a PI-Scel site, and a 3' homology arm containing -28 kb of mouse genomic sequence including the endogenous Ck2-JR4-Ck4 gene segments, the mouse enhancer 2.4 sequence and additional mouse genomic sequence downstream (3') of the enhancer 2.4 (FIG. 4A). [00229] In a similar fashion, the 12/ 1 -K Targeting Vector (FIG. 4B) employed the same -124 human k fragment with the exception that mouse homology arms containing mouse K sequence were used such that targeting to the endogenous K locus could be achieved by homologous recombination. Thus, the 1 2 /1-K Targeting Vector included, from 5' to 3', a 5' homology arm containing -23 kb of mouse genomic sequence 5' of the endogenous K locus, an I-Ceul site, a 5' Frt site, a neomycin cassette, a 3' Frt site, -124 kb of human genomic k sequence containing the first 12 consecutive hVA. gene segments and a hJR1 gene segment, a PI-Scel site, and a 3' homology arm containing -28 kb of mouse genomic sequence including the endogenous the mouse CK gene, Exi and EK3' and additional mouse genomic sequence downstream (3') of EK3' (FIG. 4B, 12/1-K Targeting Vector). 41 WO 2011/163311 PCT/US2011/041366 [00230] Homologous recombination with either of these two initial targeting vectors created a modified mouse light chain locus (K or k) containing 12 hV gene segments and a hJ1 gene segment operably linked to the endogenous mouse light chain constant gene and enhancers (Cx or C2 and EKi/Ex3' or Enh 2.4/Enh 3.1) gene which, upon recombination, leads to the formation of a chimeric k light chain. [00231] A human X mini-locus with 12 human VX and four human Jk gene segments. In another approach to add diversity to a chimeric k light chain locus, a third initial targeting vector was engineered to insert the first 12 consecutive human VA gene segments from cluster A and hJk1, 2, 3 and 7 gene segments into the mouse K light chain locus (FIG. 4B, 1 2 /4-< Targeting Vector). A DNA segment containing hJR1, JR2, JR3 and JR7 gene segments was made by de novo DNA synthesis (Integrated DNA Technologies) including each JR gene segment and human genomic sequence of -100 bp from both the immediate 5' and 3' regions of each JR gene segment. A PI-Scel site was engineered into the 3' end of this -1 kb DNA fragment and ligated to a chloroamphenicol cassette. Homology arms were PCR amplified from human k sequence at 5' and 3' positions relative to the hJX1 gene segment of the human BAC clone 729g4. Homologous recombination with this intermediate targeting vector was performed on a modified 729g4 BAC clone that had been previously targeted upstream (5') of the human Vk3-12 gene segment with a neomycin cassette flanked by Frt sites, which also contained an I-Ceul site 5' to the 5' Frt site. The double-targeted 729g4 BAC clone included from 5' to 3' an I-Ceul site, a 5' Frt site, a neomycin cassette, a 3' Frt site, a -123 kb fragment containing the first 12 hVk gene segments, a -1 kb fragment containing human JR1, 2, 3 and 7 gene segments, a PI-Scel site, and a chloroamphenicol cassette. This intermediate targeting vector was digested together with |-Ceul and PI-Scel and subsequently ligated into the modified mouse BAC clone (described above) to create the third targeting vector. [00232] This ligation resulted in a third targeting vector for insertion of human X sequences into the endogenous K light chain locus, which included, from 5' to 3', a 5' mouse homology arm containing -23 kb of genomic sequence 5' of the endogenous mouse K locus, an I-Ceul site, a 5' Frt site, a neomycin cassette, a 3' Frt site, a -123 kb fragment containing the first 12 hVX gene segments, a -1 kb fragment containing hJR1, 2, 3 and 7 gene segments, a PI-Scel site and a 3' homology arm containing -28 kb of mouse genomic sequence including the endogenous the mouse CK gene, EKi and EK3' and additional mouse genomic sequence downstream (3') of EK3' (FIG. 4B, 1 2
/
4 -K Targeting Vector). Homologous recombination with this third targeting vector created a modified mouse K light chain locus containing 12 hV gene segments and four hJR gene segments 42 WO 2011/163311 PCT/US2011/041366 operably linked to the endogenous mouse CK gene which, upon recombination, leads to the formation of a chimeric human /mouse K light chain. [00233] A human , mini-locus with an integrated human K light chain sequence. In a similar fashion, two additional targeting vectors similar to those engineered to make an initial insertion of human k gene segments into the endogenous K light chain locus (FIG. 4B, 1 2 /1-K and 12/ 4 -K Targeting Vectors) were engineered to progressively insert human k light chain gene segments using uniquely constructed targeting vectors containing contiguous human X and K genomic sequences. These targeting vectors were constructed to include a ~ 23 kb human K genomic sequence naturally located between human VK4-1 and JK1 gene segments. This human K genomic sequence was specifically positioned in these two additional targeting vectors between human VX and human JR gene segments (FIG. 4B, 1 2 (K)1-< and 1 2
(K)
4 -K Targeting Vectors). [00234] Both targeting vectors containing the human K genomic sequence were made using the modified RP11-729g4 BAC clone described above (FIG. 6). This modified BAC clone was targeted with a spectinomycin selection cassette flanked by Notl and AsiSI restriction sites (FIG.6, top left). Homologous recombination with the spectinomycin cassette resulted in a double-targeted 729g4 BAC clone which included, from 5' to 3', an I Ceul site, a 5' Frt site, a neomycin cassette, a 3' Frt site, a -123 kb fragment containing the first 12 hVk gene segments, a Notl site about 200 bp downstream (3') to the nonamer sequence of the hVk3-1 gene segment, a spectinomycin cassette and an AsiSI site. A separate human BAC clone containing human K sequence (CTD-2366j12) was targeted two independent times to engineer restriction sites at locations between hVK4-1 and hJ1 gene segments to allow for subsequent cloning of a -23 kb fragment for ligation with the hV gene segments contained in the double targeted modified 729g4 BAC clone (FIG. 6, top right). [00235] Briefly, the 2366j12 BAC clone is about 132 kb in size and contains hVK gene segments 1-6, 1-5, 2-4, 7-3, 5-2, 4-1, human K genomic sequence down stream of the VK gene segments, hJK gene segments 1-5, the hCK and about 20 kb of additional genomic sequence of the human x locus. This clone was first targeted with a targeting vector containing a hygromycin cassette flanked by Frt sites and a Notl site downstream (3') of the 3' Frt site. The homology arms for this targeting vector contained human genomic sequence 5' and 3' of the VK gene segments within the BAC clone such that upon homologous recombination with this targeting vector, the VK gene segments were deleted and a Notl site was engineered -133 bp downstream of the hVK4-1 gene segment (FIG. 6, top right). This modified 2366j12 BAC clone was targeted independently with two targeting 43 WO 2011/163311 PCT/US2011/041366 vectors at the 3' end to delete the hJK gene segments with a chloroamphenicol cassette that also contained either a hJk1 gene segment, a PI-Scel site and an AsiSI site or a human k genomic fragment containing four hJk gene segments (supra), a PI-Scel site and an AsiSI site (FIG. 6, top right). The homology arms for these two similar targeting vectors contained sequence 5' and 3' of the hJK gene segments. Homologous recombination with these second targeting vectors and the modified 2366j1 2 BAC clone yielded a double targeted 2366j12 clone which included, from 5' to 3', a 5' Frt site, a hygromycin cassette, a 3' Frt site, a Notl site, a 22,800 bp genomic fragment of the human x locus containing the intergenic region between the VK4-1 and JK1 gene segments, either a hJk1 gene segment or a human k genomic fragment containing hJk1, JR2, JX3 and JR7, a PI-Scel site and a chloroamphenicol cassette (FIG. 6, top right). Two final targeting vectors to make the two additional modifications were achieved by two ligation steps using the double-targeted 729g4 and 2366j12 clones. [00236] Double targeted 729g4 and 2366j12 clones were digested with Notl and AsiSI yielding one fragment containing the neomycin cassette and hVk gene segments and another fragment containing the -23 kb genomic fragment of the human K locus containing the intergenic region between the Vx4-1 and JK1 gene segments, either a hJR1 gene segment or a genomic fragment containing hJR1, JX2, JX3 and JR7 gene segments, the PI Scel site and the chloroamphenicol cassette, respectively. Ligation of these fragments generated two unique BAC clones containing from 5' to 3' the hVx gene segments, the human K genomic sequence between the VK4-1 and J1 gene segments, either a hJR1 gene segment or a genomic fragment containing hJR1, JR2, JA3 and JR7 gene segments, a PI-Scel site and a chloroamphenicol cassette (FIG. 6, bottom). These new BAC clones were then digested with I-Ceul and PI-Scel to release the unique fragments containing the upstream neomycin cassette and the contiguous human k and K sequences and ligated into a modified mouse BAC clone 302g12 which contained from 5' to 3' mouse genomic sequence 5' of the endogenous K locus, an I-Ceul site, a 5' Frt site, a neomycin cassette, a 3' Frt site, hVk gene segments (3-12 to 3-1), a NotI site -200 bp downstream of Vk3-1, -23 kb of human K sequence naturally found between the human VK4-1 and J1 gene segments, either a hJR1 gene segment or a genomic fragment containing hJR1, JR2, JR3 and JR7 gene segments, the mouse EKi, the mouse CK gene and EK3' (FIG. 4, 12hVk VxJK-hJR1 and 12hVk-VKJK-4hJR Targeting Vectors). Homologous recombination with both of these targeting vectors created two separate modified mouse K light chain loci containing 12 hVA gene segments, human K genomic sequence, and either one or four hJR 44 WO 2011/163311 PCT/US2011/041366 gene segments operably linked to the endogenous mouse CK gene which, upon recombination, leads to the formation of a chimeric human /mouse K light chain. Example liI Engineering Additional Human VX Genes Segments Into a Human X Light Chain Mini-Locus [00237] Additional hVk gene segments were added independently to each of the initial modifications described in Example 2 using similar targeting vectors and methods (FIG. 5A, +16-X Targeting Vector and FIG. 5B, +1 6 -K Targeting Vector). [00238] Introduction of 16 additional human VX gene segments. Upstream (5') homology arms used in constructing targeting vectors for adding 16 additional hVX gene segments to the modified light chain loci described in Example 2 contained mouse genomic sequence 5' of either the endogenous K or k light chain loci. The 3' homology arms were the same for all targeting vectors and contained human genomic sequence overlapping with the 5' end of the human k sequence of the modifications as described in Example 2. [00239] Briefly, two targeting vectors were engineered for introduction of 16 additional hVX gene segments to the modified mouse light chain loci described in Example 2 (FIG. 5A and 5B, +16-X or +1 6 -K Targeting Vector). A -172 kb DNA fragment from human BAC clone RP1 1-761113 (Invitrogen) containing 21 consecutive hVk gene segments from cluster A was engineered with a 5' homology arm containing mouse genomic sequence 5' to either the endogenous K or k light chain loci and a 3' homology arm containing human genomic k sequence. The 5' mouse x or k homology arms used in these targeting constructs were the same 5' homology arms described in Example 2 (FIG. 5A and 5B). The 3' homology arm included a 53,057 bp overlap of human genomic k sequence corresponding to the equivalent 5' end of the -123 kb fragment of human genomic k sequence described in Example 2. These two targeting vectors included, from 5' to 3', a 5' mouse homology arm containing either -23 kb of genomic sequence 5' of the endogenous mouse K light chain locus or -24 kb of mouse genomic sequence 5' of the endogenous k light chain locus, a 5' Frt site, a hygromycin cassette, a 3' Frt site and 171,457 bp of human genomic k sequence containing 21 consecutive hVA gene segments, -53 kb of which overlaps with the 5' end of the human k sequence described in Example 3 and serves as the 3' homology arm for this targeting construct (FIG. 5A and 5B, +16-k or +1 6 -K Targeting Vectors). Homologous recombination with these targeting vectors created independently modified mouse K and k light chain loci each containing 28 hVK gene segments and a hJk1 gene segment operably 45 WO 2011/163311 PCT/US2011/041366 linked to endogenous mouse constant genes (Cx or CK2) which, upon recombination, leads to the formation of a chimeric light chain. [00240] In a similar fashion, the +1 6-K Targeting Vector was also used to introduce the 16 additional hVk gene segments to the other initial modifications described in Example 2 that incorporated multiple hJK gene segments with and without an integrated human K sequence (FIG. 4B). Homologous recombination with this targeting vector at the endogenous mouse K locus containing the other initial modifications created mouse K light chain loci containing 28 hVk gene segments and hJk1, 2, 3 and 7 gene segments with and without a human VK-Jx genomic sequence operably linked to the endogenous mouse CK gene which, upon recombination, leads to the formation of a chimeric k-K light chain. [00241] Introduction of 12 additional human V) gene segments. Additional hVK gene segments were added independently to each of the modifications described above using similar targeting vectors and methods. The final locus structure resulting from homologous recombination with targeting vectors containing additional hVK gene segments are shown in FIG. 7A and 7B. [00242] Briefly, a targeting vector was engineered for introduction of 12 additional hVK gene segments to the modified mouse K and k light chain loci described above (FIG. 5A and 5B, +12-k or 1 2 -x Targeting Vectors). A 93,674 bp DNA fragment from human BAC clone RP1 1-22118 (Invitrogen) containing 12 consecutive hVK gene segments from cluster B was engineered with a 5' homology arm containing mouse genomic sequence 5' to either the endogenous mouse K or k light chain loci and a 3' homology arm containing human genomic k sequence. The 5' homology arms used in this targeting construct were the same 5' homology arms used for the addition of 16 hVK gene segments described above (FIG. 5A and 5B). The 3' homology arm was made by engineering a PI-Scel site -3431 bp 5' to the human VK3-29P gene segment contained in a 27,468 bp genomic fragment of human k sequence from BAC clone RP11-761113. This PI-Scel site served as a ligation point to join the -94 kb fragment of additional human K sequence to the -27 kb fragment of human K sequence that overlaps with the 5' end of the human K sequence in the previous modification using the +16-K or +16-x Targeting Vectors (FIG. 5A and 5B). These two targeting vectors included, from 5' to 3', a 5' homology arm containing either -23 kb of mouse genomic sequence 5' of the endogenous K light chain locus or -24 kb of mouse genomic sequence 5' of the endogenous k light chain locus, a 5' Frt site, a neomycin cassette, a 3' Frt site and 121,188 bp of human genomic k sequence containing 16 hVK gene segments and a PI-Scel site, -27 kb of which overlaps with the 5' end of the human k sequence from the insertion of 16 addition hVk gene segments and serves as the 3' 46 WO 2011/163311 PCT/US2011/041366 homology arm for this targeting construct (FIG. 5A and 5B, +12-X or 1 2 -K Targeting Vectors). Homologous recombination with these targeting vectors independently created modified mouse K and k light chain loci containing 40 hVA gene segments and human Jk1 operably linked to the endogenous mouse constant genes (CK or C2) which, upon recombination, leads to the formation of a chimeric light chain (bottom of FIG.5A and 5B). [00243] In a similar fashion, the +1 2 -K Targeting Vector was also used to introduce the 12 additional hVk gene segments to the other initial modifications that incorporated multiple hJk gene segments with and without an integrated human K sequence (FIG. 4B). Homologous recombination with this targeting vector at the endogenous mouse K locus containing the other modifications created a mouse K light chain locus containing 40 hVA gene segments and hJk1, 2, 3 and 7 gene segments with and without a human VK-JK genomic sequence operably linked to the endogenous mouse CK gene which, upon recombination, leads to the formation of a chimeric X-K light chain. Example IV Identification of targeted ES cells Bearing Human X Light Chain Gene Segments [00244] Targeted BAC DNA made according to the foregoing Examples was used to electroporate mouse ES cells to create modified ES cells for generating chimeric mice that express human k light chain gene segments. ES cells containing an insertion of unrearranged human k light chain gene segments were identified by a quantitative TAQMAN@ assay. Specific primers sets and probes were design for insertion of human k sequences and associated selection cassettes (gain of allele, GOA), loss of endogenous mouse sequences and any selection cassettes (loss of allele, LOA) and retention of flanking mouse sequences (allele retention, AR). For each additional insertion of human k sequences, additional primer sets and probes were used to confirm the presence of the additional human k sequences as well as the previous primer sets and probes used to confirm retention of the previously targeted human sequences. Table 1 sets forth the primers and associated probes used in the quantitative PCR assays. Table 2 sets forth the combinations used for confirming the insertion of each section of human k light chain gene segments in ES cell clones. [00245] ES cells bearing the human k light chain gene segments are optionally transfected with a construct that expresses FLP in order to remove the Frt'ed neomycin cassette introduced by the insertion of the targeting construct containing human Vk5-52 Vk1-40 gene segments (FIG. 5A and 5B). The neomycin cassette may optionally be 47 WO 2011/163311 PCT/US2011/041366 removed by breeding to mice that express FLP recombinase (e.g., US 6,774,279). Optionally, the neomycin cassette is retained in the mice. Table 1 Primer SEQ ID NO: Probe SEQ ID NO: hL2F 2 hL2P 24 hL2R 3 hL3F 4 hL3P 25 hL3R 5 NeoF 6 NeoP 26 NeoR 7 61hJ1F 8 61hJ1P 27 61hJ1R 9 67hT1F 10 67hTIP 28 67hT1R 11 67hT3F 12 67hT3P 29 67hT3R 13 HygF 14 HygR HygP 30 HygR 15 MKD2F 16 MKD2P 31 MKD2R 17 MKP8F 18 MKP8P 32 MKP8R 19 MKP15F 20 MKP15P 33 MKP15R 21 MK20F 22 MKP4R 23 68h2F 34 68h2P 38 68h2R 35 68h5F 36 68h5P 39 68h5R 37 mL1F 75 mL1 P 83 mLIR 76 mL2F 77 mL2P 84 mL2R 78 mL11F 79 mL11P 85 mL14R 80 48 WO 2011/163311 PCT/US2011/041366 mL12F 81 mL12P 86 mL12R 82 Table 2 Modification Assay Forward/Reverse Probe Sequence Location Primer Set hL2F/hL2R hL2P Vk3-12 - hVk3-1 hL3F/hL3R hL3P GOA 61hJ1F/61hJ1R 61hJ1P hJ sequence NeoF/NeoR NeoP Neomycin cassette MK20F/MKP4R
-
ox5l 1/loxP sequence of inactivated K locus Hygromycin cassette HygF/HygR HygP from inactivated k locus Insertion of mL1 F/mL1 R mL1 P 12 hVX & hJk1 LOA Mouse Vk1-C1 Cluster mL2F/mL2R mL2P mL11F/mL11R mL11P ________Mouse VX2-CX2 Cluster mL12F/mL12R mL12P MKD2F/MKD2R MKD2P Vx ocusequence in 5' AR/LOA MKP15F/MKP15R MKP15P V ocusequence in 3' 67hT1 F/67hT1 R 67hT1 P hVk3-27 - hVX3-1 2 GOA 67hT3F/67hT3R 67hT3P HygF/HygR HygP Hygromycin cassette NeoF/NeoR NeoP Neomycin cassette mL1F/mL1R mL1P Mouse Vk1-Ck1 LOA mL2F/mL2R mL2P Cluster Insertion of mLl 1 F/mLl 1 R mL11P Mouse Vk2-Ck2 16 hVk mL12F/mL12R mL12P Cluster AR hL2F/hL2R hL2P hVX3-12 - hVk3-1 hL3F/hL3R hL3P MKD2F/MKD2R MKD2P V ocusequence in 5' AR/LOA MKP15F/MKP15R MKP15P V ocusequence in 3' 49 WO 2011/163311 PCT/US2011/041366 68h2F/68h2R 68h2P hVk5-52 - hVk1 -40 GOA 68h5F/68h5R 68h5P NeoF/NeoR NeoP Neomycin cassette HygF/HygR HygP Hygromycin cassette mL1 F/mLl R mL1 P Mouse Vk1 -Ck1 LOA mL2F/mL2R mL2P Cluster mL11F/mL11R mL11P Mouse Vk2-Ck2 Insertion of mL12F/mL12R mL12P Cluster 12 hVA hL2F/hL2R hL2P hV3-12 - hVk3-1 AR hL3F/hL3R hL3P 67hT1 F/67hT1 R 67hT1 P hVk3-27 - hVk3-12 67hT3F/67hT3R 67hT3P MKD2F/MKD2R MKD2P V ocusequence in 5' AR/LOA MKP15F/MKP15R MKP15P V ocusequence in 3' Example V Generation of Mice Expressing Human k Light Chains From an Endogenous Light Chain Locus [00246] Targeted ES cells described above were used as donor ES cells and introduced into an 8-cell stage mouse embryo by the VELOCIMOUSE@ method (see, e.g., US Pat. No. 7,294,754 and Poueymirou et al. (2007) FO generation mice that are essentially fully derived from the donor gene-targeted ES cells allowing immediate phenotypic analyses Nature Biotech. 25(1):91-99. VELOCIMICE@ (F0 mice fully derived from the donor ES cell) independently bearing human k gene segments were identified by genotyping using a modification of allele assay (Valenzuela et al., supra) that detected the presence of the unique human k gene segments (supra). [00247] c:X light chain usage of mice bearing human X light chain gene segments. Mice homozygous for each of three successive insertions of hVk gene segments with a single hJk gene segment (FIG. 5B) and mice homozygous for a first insertion of hVX gene segments with either a single hJk gene segment or four human JR gene segments including a human VK-JK genomic sequence (FIG. 4B) were analyzed for K and X light chain expression in splenocytes using flow cytometry. [00248] Briefly, spleens were harvested from groups of mice (ranging from three to seven animals per group) and grinded using glass slides. Following lysis of red blood cells (RBCs) with ACK lysis buffer (Lonza Walkersville), splenocytes were stained with fluorescent dye conjugated antibodies specific for mouse CD19 (Clone 1D3; BD 50 WO 2011/163311 PCT/US2011/041366 Biosciences), mouse CD3 (17A2; Biolegend), mouse Igw (187.1; BD Biosciences) and mouse IgX (RML-42; Biolegend). Data was acquired using a BD T M LSR 11 flow cytometer (BD Biosciences) and analyzed using FLOWJO TM software (Tree Star, Inc.). Table 3 sets forth the average percent values for B cells (CD19*), K light chain (CD19*IgK'Igk-), and X light chain (CD1 9*Igi~Igk*) expression observed in splenocytes from groups of animals bearing each genetic modification. [00249] In a similar experiment, B cell contents of the splenic compartment from mice homozygous for a first insertion of 12 hVk and four hJ gene segments including a human VK-JK genomic sequence operably linked to the mouse CK gene (bottom of FIG. 4B) and mice homozygous for 40 hVk and one hJX gene segment (bottom of FIG. 5B or top of FIG. 7B) were analyzed for Igw and lgk expression using flow cytometry (as described above). FIG. 8A shows the IgX and IgK expression in CD19' B cells for a representative mouse from each group. The number of CD19* B cells per spleen was also recorded for each mouse (FIG. 8B). [00250] In another experiment, B cell contents of the spleen and bone marrow compartments from mice homozygous for 40 hVX and four hJ gene segments including a human Vx-Jx genomic sequence operably linked to the mouse C gene (bottom of FIG. 7B) were analyzed for progression through B cell development using flow cytometry of various cell surface markers. [00251] Briefly, two groups (N=3 each, 9-12 weeks old, male and female) of wild type and mice homozygous for 40 hVk and four hJ gene segments including a human Vx-Jx genomic sequence operably linked to the mouse CK gene were sacrificed and spleens and bone marrow were harvested. Bone marrow was collected from femurs by flushing with complete RPMI medium (RPMI medium supplemented with fetal calf serum, sodium pyruvate, Hepes, 2-mercaptoethanol, non-essential amino acids, and gentamycin). RBCs from spleen and bone marrow preparations were lysed with ACK lysis buffer (Lonza Walkersville), followed by washing with complete RPMI medium. 1x10 6 cells were incubated with anti-mouse CD16/CD32 (2.4G2, BD Biosciences) on ice for 10 minutes, followed by labeling with a selected antibody panel for 30 min on ice. [00252] Bone marrow panel: anti-mouse FITC-CD43 (1B11, BioLegend), PE-ckit (2B8, BioLegend), PeCy7-IgM (11/41, eBioscience), PerCP-Cy5.5-IgD (11-26c.2a, BioLegend), APC- B220 (RA3-6B2, eBioscience), APC-H7-CD19 (ID3, BD) and Pacific Blue-CD3 (17A2, BioLegend). [00253] Bone marrow and spleen panel: anti-mouse FITC-IgK (187.1, BD), PE-Igk (RML-42, BioLegend), PeCy7-IgM (11/41, ebioscience), PerCP-Cy5.5-IgD (11-26c.2a, 51 WO 2011/163311 PCT/US2011/041366 BioLegend), Pacific Blue-CD3 (17A2, BioLegend), APC- B220 (RA3-6B2, eBioscience), APC-H7-CD19 (ID3, BD). [00254] Following staining, cells were washed and fixed in 2% formaldehyde. Data acquisition was performed on a FACSCANTOII T M flow cytometer (BD Biosciences) and analyzed with FLOWJO TM software (Tree Star, Inc.). FIGs. 9A - 9D show the results for the splenic compartment of one representative mouse from each group. FIGs. 1 0A - 1 0E show the results for the bone marrow compartment of one representative mouse from each group. Table 4 sets forth the average percent values for B cells (CD19*), x light chain (CD1 9lgKlgk-), and X light chain (CD19*1gl-Igk) expression observed in splenocytes from groups of animals bearing various genetic modifications. Table 5 sets forth the average percent values for B cells (CD19*), mature B cells (B220hilgM+), immature B cells (B220'ntIgM+), immature B cells expressing x light chain (B220"tigM+gK+) and immature B cells expressing k light chain (B220ntigM+lgk+) observed in bone marrow of wild type and mice homozygous for 40 hVk and four hJk gene segments including a human VK-JK genomic sequence operably linked to the mouse Cx gene. This experiment was repeated with additional groups of the mice described above and demonstrated similar results (data not shown). Table 3 Genotype % B cells % Igi* % IgX* Wild Type 46.2 91.0 3.6 12 hVk+hJk1 28.3 10.4 62.5 12 hVk-VxJK-hJ?1 12.0 11.0 67.5 12 hVk-VxJK-4hJR 41.8 17.2 68.4 28 hVk+hJk1 22.0 13.3 51.1 40 hVk+hJk1 28.2 24.3 53.0 Table 4 Genotype % B cells % lgK+ % +gX+ Wild Type 49.8 j91.2 3.5 40 hVk-VwJK-4hJK 33.3 41.6 43.1 52 WO 2011/163311 PCT/US2011/041366 Table 5 Genotype B Mature Immature Immature Immature cells B cells B cells lgix B cells igX* B cells Wild Type 62.2 9.2 12.0 79.0 8.84 V4J-4hJ 60.43 2.59 7.69 38.29 43.29 [00255] Human V% gene usage in mice bearing human , light chain gene segments. Mice heterozygous for a first insertion of human k sequences (hVk3-12 hVk3-1 and hJX1, FIG. 5B) and homozygous for a third insertion of human X sequences (hVX5-52 - hVk3-1 and hJkl, FIG. 5B) were analyzed for human k light chain gene usage by reverse-transcriptase polymerase chain reaction (RT-PCR) using RNA isolated from splenocytes. [00256] Briefly, spleens were harvested and perfused with 10 mL RPMI-1 640 (Sigma) with 5% HI-FBS in sterile disposable bags. Each bag containing a single spleen was then placed into a STOMACHER T M (Seward) and homogenized at a medium setting for 30 seconds. Homogenized spleens were filtered using a 0.7pm cell strainer and then pelleted with a centrifuge (1000 rpm for 10 minutes) and RBCs were lysed in BD PHARM LYSE TM (BD Biosciences) for three minutes. Splenocytes were diluted with RPMI-1640 and centrifuged again, followed by resuspension in 1 mL of PBS (Irvine Scientific). RNA was isolated from pelleted splenocytes using standard techniques known in the art. [00257] RT-PCR was performed on splenocyte RNA using primers specific for human hVX gene segments and the mouse CK gene (Table 6). PCR products were gel-purified and cloned into pCR2.1-TOPO TA vector (Invitrogen) and sequenced with primers M13 Forward (GTAAAACGAC GGCCAG; SEQ ID NO:55) and M13 Reverse (CAGGAAACAG CTATGAC; SEQ ID NO:56) located within the vector at locations flanking the cloning site. Eighty-four total clones derived from the first and third insertions of human X sequences were sequenced to determine hVX gene usage (Table 7). The nucleotide sequence of the hVk-hJk1-mCK junction for selected RT-PCR clones is shown in FIG. 11. [00258] In a similar fashion, mice homozygous for a third insertion of human k light chain gene sequences (i.e. 40 hVA gene segments and four hJk gene segments including a human VK-JK genomic sequence, bottom of FIG. 7B) operably linked to the endogenous mouse Cx gene were analyzed for human k light chain gene usage by RT-PCR using RNA 53 WO 2011/163311 PCT/US2011/041366 isolated from splenocytes (as described above). The human k light chain gene segment usage for 26 selected RT-PCR clones are shown in Table 8. The nucleotide sequence of the hVk-hJk-mCK junction for selected RT-PCR clones is shown in FIG. 12. [00259] In a similar fashion, mice homozygous for a first insertion of human k light chain gene segments (12 hVk gene segments and hJk1, FIG. 4A & FIG. 5A) operably linked to the endogenous mouse C2 gene were analyzed for human k light chain gene usage by RT-PCR using RNA isolated from splenocytes (as described above). The primers specific for hVk gene segments (Table 6) were paired with one of two primers specific for the mouse Ck2 gene; Ck2-1 (SEQ ID NO:104) or Ck2-2 (SEQ ID NO:105). [00260] Multiple hVk gene segments rearranged to hk1 were observed from the RT PCR clones from mice bearing human k light chain gene segments at the endogenous mouse k light chain locus. The nucleotide sequence of the hVk-hJk-mCk2 junction for selected RT-PCR clones is shown in FIG. 13. Table 6 hV Primer Sequence (5'-3') SEQ ID VLL-1 CCTCTCCTCC TCACCCTCCT 40 VLL-1 n ATGRCCDGST YYYCTCTCCT 41 VLL-2 CTCCTCACTC AGGGCACA 42 VLL-2n ATGGCCTGGG CTCTGCTSCT 43 VLL-3 ATGGCCTGGA YCSCTCTCC 44 VLL-4 TCACCATGGC YTGGRYCYCM YTC 45 VLL-4.3 TCACCATGGC CTGGGTCTCC TT 46 VLL-5 TCACCATGGC CTGGAMTCYT CT 47 VLL-6 TCACCATGGC CTGGGCTCCA CTACTT 48 VLL-7 TCACCATGGC CTGGACTCCT 49 VLL-8 TCACCATGGC CTGGATGATG CTT 50 VLL-9 TAAATATGGC CTGGGCTCCT CT 51 VLL-10 TCACCATGCC CTGGGCTCTG CT 52 VLL-1 1 TCACCATGGC CCTGACTCCT CT 53 3' Mouse Sequence (5'-3') SEQ ID Cx Primer NO: mIgKC3'-1 CCCAAGCTTA CTGGATGGTG GGAAGATGGA 54 54 WO 2011/163311 PCT/US2011/041366 Table 7 Table 8 hVA Observed No. Clone hVX hJX of Clones 3-1 2 1-3 1-44 7 4-3 3 1-5 1-51 3 2-8 7 2-3 9-49 7 3-9 4 2-5 1-40 1 3-10 3 2-6 1-40 7 2-14 1 3b-5 3-1 7 3-19 1 4a-1 4-3 7 2-23 7 4a-5 4-3 7 3-25 1 4b-1 1-47 3 1-40 9 5-1 3-10 3 7-43 2 5-2 1-40 7 1-44 2 5-3 1-40 7 5-45 8 5-4 7-46 2 7-46 3 5-6 1-40 7 9-49 6 5-7 7-43 3 1-51 3 6-1 1-40 1 6-2 1-40 2 6-7 1-40 3 7a-1 3-10 7 7a-2 9-49 2 7a-7 3-10 7 7b-2 7-43 3 7b-7 7-46 7 7b-8 7-43 3 11a-1 5-45 2 11a-2 5-45 7 [00261] FIG. 11 shows the sequence of the hVk-hJk1-mCK junction for RT-PCR clones from mice bearing a first and third insertion of hVX gene segments with a single hJk gene segment. The sequences shown in FIG. 11 illustrate unique rearrangements involving different hVk gene segments with hJR1 recombined to the mouse Cix gene. Heterozygous mice bearing a single modified endogenous K locus containing 12 hVk gene segments and hJR1 and homozygous mice bearing two modified endogenous K loci containing 40 hVk gene segments and hJk1 were both able to produce human k gene segments operably 55 WO 2011/163311 PCT/US2011/041366 linked to the mouse CK gene and produce B cells that expressed human k light chains. These rearrangements demonstrate that the chimeric loci were able to independently rearrange human k gene segments in multiple, independent B cells in these mice. Further, these modifications to the endogenous K light chain locus did not render any of the hVk gene segments inoperable or prevent the chimeric locus from recombining multiple hVk and a hJk (Jk1) gene segment during B cell development as evidenced by 16 different hVk gene segments that were observed to rearrange with hJR1 (Table 7). Further, these mice made functional antibodies containing rearranged human VX-JX gene segments operably linked to mouse CK genes as part of the endogenous immunoglobulin light chain repertoire. [00262] FIG. 12 shows the sequence of the hVk-hJk-mCK junction for selected RT-PCR clones from mice homozygous for 40 hVk and four hJR gene segments including a human VK-JK genomic sequence. The sequences shown in FIG. 12 illustrate additional unique rearrangements involving multiple different hVk gene segments, spanning the entire chimeric locus, with multiple different hJR gene segments rearranged and operably linked to the mouse CK gene. Homozygous mice bearing modified endogenous K loci containing 40 hVk and four hJX gene segments were also able to produce human k gene segments operably linked to the mouse CK gene and produce B cells that expressed human k light chains. These rearrangements further demonstrate that the all stages of chimeric loci were able to independently rearrange human k gene segments in multiple, independent B cells in these mice. Further, these additional modifications to the endogenous K light chain locus demonstrates that each insertion of human k gene segments did not render any of the hVk and/or JR gene segments inoperable or prevent the chimeric locus from recombining the hVk and JR gene segments during B cell development as evidenced by 12 different hVk gene segments that were observed to rearrange with all four hJR gene segments (Table 8) from the 26 selected RT-PCR clone. Further, these mice as well made functional antibodies containing human VX-JX gene segments operably linked to mouse CK regions as part of the endogenous immunoglobulin light chain repertoire. [00263] FIG. 13 shows the sequence of the hVk-hJk-mCk2 junction for three individual RT-PCR clones from mice homozygous for 12 hVk gene segments and hJ1. The sequences shown in FIG. 13 illustrate additional unique rearrangements involving different hVX gene segments, spanning the length of the first insertion, with hJR1 rearranged and operably linked to the mouse Ck2 gene (2D1 = VX2-8JR1; 2D9 = Vk3-1 0J1; 3E1 5 = Vk3 1Jk1). One clone demonstrated a nonproductive rearrangement due to N additions at the hVk-hJk junction (2D1, FIG.13). This is not uncommon in V(D)J recombination, as the 56 WO 2011/163311 PCT/US2011/041366 joining of gene segments during recombination has been shown to be imprecise. Although this clone represents an unproductive recombinant present in the light chain repertoire of these mice, this demonstrates that the genetic mechanism that contributes to junctional diversity among antibody genes is operating normally in these mice and leading to an antibody repertoire containing light chains with greater diversity. [00264] Homozygous mice bearing modified endogenous k loci containing 12 hVk gene segments and hJX1 were also able to produce human k gene segments operably linked to an endogenous mouse CX gene and produce B cells that expressed reverse chimeric k light chains containing hVX regions linked to mouse Ck regions. These rearrangements further demonstrate that human X light chain gene segments placed at the other light chain locus (i.e., the k locus) were able to independently rearrange human X gene segments in multiple, independent B cells in these mice. Further, the modifications to the endogenous k light chain locus demonstrate that the insertion of human k gene segments did not render any of the hVX and/or hJR1 gene segments inoperable or prevent the chimeric locus from recombining the hVk and hJR1 gene segments during B cell development. Further, these mice also made functional antibodies containing human VX-JX gene segments operably linked to a mouse C? region as part of the endogenous immunoglobulin light chain repertoire. [00265] As shown in this Example, mice bearing human k light chain gene segments at the endogenous K and k light chain loci are capable of rearranging human k light chain gene segments and expressing them in the context of a mouse CK and/or Ck region as part of the normal antibody repertoire of the mouse because a functional light chain is required at various checkpoints in B cell development in both the spleen and bone marrow. Further, early subsets of B cells (e.g., pre-, pro- and transitional B cells) demonstrate a normal phenotype in these mice as compared to wild type littermates (FIGs. 9D, 10A and 1OB). A small deficit in bone marrow and peripheral B cell populations was observed, which may be attributed to a deletion of a subset of auto-reactive immature B cells and/or a suboptimal association of human k light chain with mouse heavy chain. However, the IgK/Igk usage observed in these mice demonstrates a situation that is more like human light chain expression than that observed in mice. Example VI Breeding of Mice Expressing Human X Light Chains From an Endogenous Light Chain Locus [00266] To optimize the usage of the human X gene segments at an endogenous mouse light chain locus, mice bearing the unrearranged human k gene segments are bred 57 WO 2011/163311 PCT/US2011/041366 to another mouse containing a deletion in the opposing endogenous light chain locus (either K or k). For example, human k gene segments positioned at the endogenous K locus would be the only functional light chain gene segments present in a mouse that also carried a deletion in the endogenous k light chain locus. In this manner, the progeny obtained would express only human k light chains as described in the foregoing examples. Breeding is performed by standard techniques recognized in the art and, alternatively, by commercial companies, e.g., The Jackson Laboratory. Mouse strains bearing human k light chain gene segments at the endogenous K locus and a deletion of the endogenous k light chain locus are screened for presence of the unique reverse-chimeric (human-mouse) k light chains and absence of endogenous mouse k light chains. [00267] Mice bearing an unrearranged human k light chain locus are also bred with mice that contain a replacement of the endogenous mouse heavy chain variable gene locus with the human heavy chain variable gene locus (see US 6,596,541, Regeneron Pharmaceuticals, the VELOCIMMUNE@ genetically engineered mouse). The VELOCIMMUNE@ mouse includes, in part, having a genome comprising human heavy chain variable regions operably linked to endogenous mouse constant region loci such that the mouse produces antibodies comprising a human heavy chain variable region and a mouse heavy chain constant region in response to antigenic stimulation. The DNA encoding the variable regions of the heavy chains of the antibodies can be isolated and operably linked to DNA encoding the human heavy chain constant regions. The DNA can then be expressed in a cell capable of expressing the fully human heavy chain of the antibody. Upon a suitable breeding schedule, mice bearing a replacement of the endogenous mouse heavy chain locus with the human heavy chain locus and an unrearranged human k light chain locus at the endogenous K light chain locus is obtained. Antibodies containing somatically mutated human heavy chain variable regions and human k light chain variable regions can be isolated upon immunization with an antigen of interest. Example VII Generation of Antibodies From Mice Expressing Human Heavy Chains and Human X Light Chains [00268] After breeding mice that contain the unrearranged human k light chain locus to various desired strains containing modifications and deletions of other endogenous Ig loci (as described above), selected mice are immunized with an antigen of interest. [00269] Generally, a VELOCIMMUNE@ mouse containing one of the single rearranged human germline light chain regions is challenged with an antigen, and lymphatic cells (such as B-cells) are recovered from serum of the animals. The lymphatic cells may be 58 WO 2011/163311 PCT/US2011/041366 fused with a myeloma cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies containing human heavy chain and human k light chain that are specific to the antigen used for immunization. DNA encoding the variable regions of the heavy chains and the k light chains may be isolated and linked to desirable isotypic constant regions of the heavy chain and light chain. Due to the presence of the additional hVk gene segments as compared to the endogenous mouse k locus, the diversity of the light chain repertoire is dramatically increased and confers higher diversity on the antigen-specific repertoire upon immunization. The resulting cloned antibody sequences may be subsequently produced in a cell, such as a CHO cell. Alternatively, DNA encoding the antigen-specific chimeric antibodies or the variable domains of the light and heavy chains may be isolated directly from antigen-specific lymphocytes (e.g., B cells). [00270] Initially, high affinity chimeric antibodies are isolated having a human variable region and a mouse constant region. As described above, the antibodies are characterized and selected for desirable characteristics, including affinity, selectivity, epitope, etc. The mouse constant regions are replaced with a desired human constant region to generate the fully human antibody containing a somatically mutated human heavy chain and a human X light chain derived from an unrearranged human k light chain locus of the invention. Suitable human constant regions include, for example wild type or modified IgG1, IgG2, IgG3, or IgG4. 59
Claims (22)
1. A mouse comprising in its germline, at an endogenous mouse light chain locus, a human k light chain variable region sequence, wherein the human lambda variable region sequence is expressed in a light chain that comprises a mouse immunoglobulin constant region gene sequence.
2. The mouse of claim 1, wherein the endogenous mouse light chain locus is a k locus.
3. The mouse of claim 1, wherein the endogenous mouse light chain locus is a K locus.
4. The mouse of claim 1, wherein the mouse lacks an endogenous light chain variable sequence at the endogenous mouse light chain locus.
5. The mouse of claim 1, wherein all or substantially all endogenous mouse light chain variable region gene segments are replaced with one or more human k variable region gene segments.
6. The mouse of claim 1, wherein the human k light chain variable region sequence comprises a human JR sequence.
7. The mouse of claim 6, wherein the human JR sequence is selected from the group consisting of JR1, JR2, JR3, JR7, and a combination thereof.
8. The mouse of claim 1, wherein the human k light chain variable region sequence comprises a fragment of cluster A of the human light chain locus.
9. The mouse of claim 8, wherein the fragment of cluster A of the human k light chain locus extends from hVk3-27 through hV3-1.
10. The mouse of claim 1, wherein the human k light chain variable region sequence comprises a fragment of cluster B of the human light chain locus. 60 WO 2011/163311 PCT/US2011/041366
11. The mouse of claim 10, wherein the fragment of cluster B of the human k light chain locus extends from hVk5-52 through hVk1-40.
12. The mouse of claim 1, wherein the human k light chain variable region sequence comprises a genomic fragment of cluster A and a genomic fragment of cluster B.
13. The mouse of claim 12, wherein the human k light chain variable region sequence comprises at least one gene segment of cluster A and at least one gene segment of cluster B.
14. The mouse of claim 1, wherein more than 10% of the light chain repertoire of the mouse is derived from at least two hVk gene segments selected from 2-8, 2-23, 1-40, 5-45, and 9-49.
15. The mouse of claim 14, wherein more than 20% of the light chain repertoire of the mouse is derived from at least three hVk gene segments selected from 2-8, 2-23, 1-40, 5-45, and 9-49.
16. The mouse of claim 15, wherein more than 30% of the light chain repertoire of the mouse is derived from at least four hVk gene segments selected from 2-8, 2-23, 1-40, 5-45, and 9-49.
17. A mouse that expresses an immunoglobulin light chain that comprises a human lambda variable sequence fused with a mouse constant region, wherein the mouse exhibits a K usage to k usage ratio of about 1:1.
18. The mouse of claim 17, wherein the immunoglobulin light chain is expressed from an endogenous mouse light chain locus.
19. Use of a mouse as described in any one of the preceding claims to make an antigen-binding protein.
20. Use according to claim 19, wherein the antigen-binding protein is human.
21. A cell or tissue derived from a mouse of any one of claims 1-18. 61 WO 2011/163311 PCT/US2011/041366 AMENDED CLAIMS received by the International Bureau on 17 November 2011 (17.11.2011) 1. A mouse comprising in its germline, at an endogenous immunoglobulin light chain locus, a human immunoglobulin k light chain variable region nucleic acid sequence, wherein the human immunoglobulin X, variable region nucleic acid sequence is expressed in an immunoglobulin light chain that comprises a mouse immunoglobulin constant region nucleic acid sequence. 2. The mouse of claim 1, wherein the endogenous immunoglobulin light chain locus is an immunoglobulin k locus. 3. The mouse of claim 1, wherein the endogenous immunoglobulin light chain locus is an immunoglobulin -x locus. 4. The mouse of claim 1, wherein the mouse lacks an endogenous immunoglobulin light chain variable sequence at the endogenous immunoglobulin light chain locus. 5. The mouse of claim 1, wherein all or substantially all endogenous immunoglobulin light chain variable region gene segments are replaced with one or more human immunoglobulin X variable region gene segments. 6. The mouse of claim 1, wherein the human immunoglobulin k light chain variable region sequence comprises a human JA sequence. 7. The mouse of claim 6, wherein the human JX sequence is selected from the group consisting of Jk1, Jk2, Jk3, JR7, and a combination thereof. 8. The mouse of claim 1, wherein the human immunoglobulin k light chain variable region sequence comprises a fragment of cluster A of the human immunoglobulin light chain locus. 9. The mouse of claim 8, wherein the fragment of cluster A of the human immunoglobulin k light chain locus extends from hVX3-27 through hVk3-1. 62 WO 2011/163311 PCT/US2011/041366 10. The mouse of claim 1, wherein the human immunoglobulin k light chain variable region sequence comprises a fragment of cluster B of the human immunoglobulin light chain locus. 11. The mouse of claim 10, wherein the fragment of cluster B of the human immunoglobulin % light chain locus extends from hVK5-52 through hVk1-40. 12. The mouse of claim 1, wherein the human immunoglobulin k light chain variable region sequence comprises a genomic fragment of cluster A and a genomic fragment of cluster B of the human immunoglobulin % light chain locus. 13. The mouse of claim 12, wherein the human immunoglobulin k light chain variable region sequence comprises at least one gene segment of cluster A and at least one gene segment of cluster B of the human immunoglobulin X light chain locus. 14. The mouse of claim 1, wherein more than 10% of the immunoglobulin light chain repertoire of the mouse is derived from at least two hVX gene segments selected from 2-8, 2-23, 1-40, 5-45, and 9-49. 15. The mouse of claim 14, wherein more than 20% of the immunoglobulin light chain repertoire of the mouse is derived from at least three hVA gene segments selected from 2 8, 2-23, 1-40, 5-45, and 9-49. 16. The mouse of claim 15, wherein more than 30% of the immunoglobulin light chain repertoire of the mouse is derived from at least four hVX gene segments selected from 2-8, 2-23, 1-40, 5-45, and 9-49. 17. A mouse that expresses an immunoglobulin light chain that comprises a human ?variable sequence fused with a mouse constant region, wherein the mouse exhibits a x usage to X usage ratio of about 1:1. 18. The mouse of claim 17, wherein the immunoglobulin light chain is expressed from an endogenous immunoglobulin light chain locus. 19. Use of a mouse as described in any one of the preceding claims to make an antigen-binding protein. 63 WO 2011/163311 PCT/US2011/041366 20. Use according to claim 19, wherein the antigen-binding protein is human. 21. A cell or tissue derived from a mouse of any one of claims 1-18, wherein the cell comprises a human immunoglobulin X light chain variable region nucleic acid sequence contiguous with an endogenous immunoglobulin light chain constant region nucleic acid sequence.
22. A method for making a somatically mutated antibody that binds to an antigen of interest, which method comprises: (a) exposing a mouse as in any one of claims 1-18 to an antigen of interest; (b) obtaining one or more B lymphocytes of the mouse of (a), wherein the one or more B lymphocytes makes an antibody that binds to the antigen of interest; and (c) identifying a nucleic acid sequence that encodes an immunoglobulin light chain of the antibody of (b), wherein the immunoglobulin light chain comprises a human immunoglobulin X light chain variable domain and a mouse immunoglobulin light chain constant domain; and (d) employing the nucleic acid sequence of (c) with a human immunoglobulin light chain constant region nucleic acid sequence to make a human antibody that binds the antigen of interest. 64
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015275243A AU2015275243B2 (en) | 2010-06-22 | 2015-12-22 | Mice expressing a light chain with human lambda variable and mouse constant regions |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35731410P | 2010-06-22 | 2010-06-22 | |
| US35731710P | 2010-06-22 | 2010-06-22 | |
| US61/357,317 | 2010-06-22 | ||
| US61/357,314 | 2010-06-22 | ||
| PCT/US2011/041366 WO2011163311A1 (en) | 2010-06-22 | 2011-06-22 | Mice expressing alight chain with human lambda variable and mouse constant regions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015275243A Division AU2015275243B2 (en) | 2010-06-22 | 2015-12-22 | Mice expressing a light chain with human lambda variable and mouse constant regions |
Publications (5)
| Publication Number | Publication Date |
|---|---|
| AU2011271043A1 true AU2011271043A1 (en) | 2013-01-31 |
| AU2011271043B2 AU2011271043B2 (en) | 2015-10-01 |
| AU2011271043A9 AU2011271043A9 (en) | 2015-10-01 |
| AU2011271043B8 AU2011271043B8 (en) | 2016-01-21 |
| AU2011271043A8 AU2011271043A8 (en) | 2016-01-21 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200239837A1 (en) | Human lambda light chain mice | |
| AU2011271043B8 (en) | Mice expressing a light chain with human lambda variable and mouse constant regions | |
| AU2015275243A1 (en) | Mice expressing a light chain with human lambda variable and mouse constant regions | |
| AU2015275242A1 (en) | Hybrid light chain mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| TH | Corrigenda |
Free format text: IN VOL 27 , NO 4 , PAGE(S) 606 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME REGENERON PHARMACEUTICALS, INC., APPLICATION NO. 2011271043, UNDER INID (72) CORRECT THE CO-INVENTOR TO MACDONALD, LYNN Free format text: IN VOL 29 , NO 38 , PAGE(S) 5876 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME REGENERON PHARMACEUTICALS, INC., APPLICATION NO. 2011271043, UNDER INID (72) CORRECT THE CO-INVENTOR TO MACDONALD, LYNN |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| TH | Corrigenda |
Free format text: IN VOL 30 , NO 3 , PAGE(S) 394 UNDER THE HEADING CORRIGENDA DELETE ALL REFERENCE TO 2011271043 Free format text: IN VOL 30 , NO 3 , PAGE(S) 393 UNDER THE HEADING CORRIGENDA DELETE ALL REFERENCE TO 2011271043. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ MICE EXPRESSING A LIGHT CHAIN WITH HUMAN LAMBDA VARIABLE AND MOUSE CONSTANT REGIONS |